var title_f14_19_14640="LV aneurysm in midcavity HCM";
var content_f14_19_14640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LV aneurysm in midcavity HCM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left ventricular cineangiogram in a patient with midcavity LV obstruction (arrow) and an apical LV aneurysm. Atrial and right ventricular pacing leads of a dual chamber pacing implanted to treat the mid-cavity obstruction are shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14640=[""].join("\n");
var outline_f14_19_14640=null;
var title_f14_19_14641="Tricuspid regurgitation Doppler";
var content_f14_19_14641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Doppler echocardiographic study showing tricuspid regurgitation in a patient with IPAH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lewis J Rubin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14641=[""].join("\n");
var outline_f14_19_14641=null;
var title_f14_19_14642="Calculator: Clinical indicators for malignant hyperthermia";
var content_f14_19_14642=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MalignantHyperthermia_form\" name=\"MalignantHyperthermia_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Clinical indicators for malignant hyperthermia",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Rigidity*",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Generalized muscular rigidity without shivering during or immediately following emergence from inhalational anesthesia (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Masseter muscle spasm shortly following succinylcholine administration (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Rhabomyolysis*",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           CK &gt;20,000 IU after anesthesia with succinylcholine (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           CK &gt;10,000 IU after anesthesia without succinylcholine (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Cola-colored urine in perioperative period (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Urine myoglobin &gt;60 mcg/L (5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Serum myoglobin &gt;170 mcg/L (5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Serum K &gt;6 meq/L (without renal failure) (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Respiratory Acidosis*",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Controlled ventilation PETCO2 &gt;55 (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Controlled ventilation PaCO2 &gt;60 (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Spontaneous ventilation PETCO2 &gt;60 (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Spontaneous ventilation PaCO2 &gt;65 (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Inappropriate hypercarbia (judgement) (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Inappropriate tachypnea (judgement) (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Fever*",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Inappropriate rapid increase in temperature (judgement) (15 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Inappropriate perioperative temperature &gt;38.8&deg;C (judgement) (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Tachycardia*",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Inappropriate sinus tachycardia (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"MalignantHyperthermia_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Ventricular tachycardia or ventricular fibrillation (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Other **",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"MalignantHyperthermia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Base excess below -8 mEq/L (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"MalignantHyperthermia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Arterial pH &lt;7.25 (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"MalignantHyperthermia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Rapid reversal of MH signs with dantrolene (5 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"MalignantHyperthermia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Positive family history together with positive personal anesthetic history (not including elevated resting CK) (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"MalignantHyperthermia_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Resting elevated serum CK (in patient with positive family history) (10 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          Malignant Hyperthermia Likelihood and MH Rank",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           MH Rank = 1 and MH likelihood is Almost never",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3-9 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           MH Rank = 2 and MH likelihood is Unlikely",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           10-19 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           MH Rank = 3 and MH likelihood is Somewhat less than likely",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           20-34 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           MH Rank = 4 and MH likelihood is Somewhat greater than likely",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_5\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           35-49 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           MH Rank = 5 and MH likelihood is Very likely",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_6\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           50-108 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           MH Rank = 6 and MH likelihood is Almost certain",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       *Do not double count; choose the indicator with highest score.",
"      </li>",
"      <li>",
"       **Ok to double count; add each applicable.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Larach MG, Localio AR, Allen GC, et. al. A clinical grading scale to predict malignant hyperthermia susceptibility.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"MalignantHyperthermia_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14642=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function MalignantHyperthermia_fx() {",
"with(document.MalignantHyperthermia_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 15;",
"}",
"if (cc1[1].checked){",
"Score = Score + 15;",
"}",
"if (cc2[0].checked){",
"Score = Score + 15;",
"}",
"if (cc2[1].checked){",
"Score = Score + 15;",
"}",
"if (cc2[2].checked){",
"Score = Score + 10;",
"}",
"if (cc2[3].checked){",
"Score = Score + 5;",
"}",
"if (cc2[4].checked){",
"Score = Score + 5;",
"}",
"if (cc2[5].checked){",
"Score = Score + 3;",
"}",
"if (cc3[0].checked){",
"Score = Score + 15;",
"}",
"if (cc3[1].checked){",
"Score = Score + 15;",
"}",
"if (cc3[2].checked){",
"Score = Score + 15;",
"}",
"if (cc3[3].checked){",
"Score = Score + 15;",
"}",
"if (cc3[4].checked){",
"Score = Score + 15;",
"}",
"if (cc3[5].checked){",
"Score = Score + 10;",
"}",
"if (cc4[0].checked){",
"Score = Score + 15;",
"}",
"if (cc4[1].checked){",
"Score = Score + 10;",
"}",
"if (cc5[0].checked){",
"Score = Score + 3;",
"}",
"if (cc5[1].checked){",
"Score = Score + 3;",
"}",
"if (cc6.checked){",
"Score = Score + 10;",
"}",
"if (cc7.checked){",
"Score = Score + 10;",
"}",
"if (cc8.checked){",
"Score = Score + 5;",
"}",
"if (cc9.checked){",
"Score = Score + 10;",
"}",
"if (cc10.checked){",
"Score = Score + 10;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 0)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 9)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 10) && (Score <= 19)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 20) && (Score <= 34)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"if ((Score >= 35) && (Score <= 49)){ document.getElementById('rr1_5').bgColor = '#cccccc';",
"}",
"if ((Score >= 50) && (Score <= 108)){ document.getElementById('rr1_6').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"document.getElementById('rr1_5').bgColor = \"\";",
"document.getElementById('rr1_6').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f14_19_14642=null;
var title_f14_19_14643="Single incision laparoscopic surgery";
var content_f14_19_14643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single incision laparoscopic surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three instruments have been introduced through a single umbilical port.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Aurora Pryor.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14643=[""].join("\n");
var outline_f14_19_14643=null;
var title_f14_19_14644="Crusted scabies scalp";
var content_f14_19_14644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crusted scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Crusted scabies in a patient with acquired immunodeficiency syndrome. The lesions resemble solar keratoses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14644=[""].join("\n");
var outline_f14_19_14644=null;
var title_f14_19_14645="Elvitegravir, cobicistat, tenofovir and emtricitabine: Patient drug information";
var content_f14_19_14645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Elvitegravir, cobicistat, tenofovir and emtricitabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/54/8041?source=see_link\">",
"     see \"Elvitegravir, cobicistat, tenofovir and emtricitabine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14944840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stribild&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16337655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Stribild&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15124941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done in patients taking this drug for HIV infection. A hepatitis B infection may get worse after this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15124943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15124942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3962334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to elvitegravir, cobicistat, emtricitabine, tenofovir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15124947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15124948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad dreams.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15124949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15124945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15124946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15124950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15124951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86613 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14645=[""].join("\n");
var outline_f14_19_14645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337655\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124941\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124943\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124942\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124947\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124948\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124949\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124945\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124946\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124950\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15124951\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/54/8041?source=related_link\">",
"      Elvitegravir, cobicistat, tenofovir and emtricitabine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_19_14646="Tolterodine: Drug information";
var content_f14_19_14646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolterodine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/25/41364?source=see_link\">",
"    see \"Tolterodine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/28/2502?source=see_link\">",
"    see \"Tolterodine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Detrol&reg;;",
"     </li>",
"     <li>",
"      Detrol&reg; LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Detrol&reg;;",
"     </li>",
"     <li>",
"      Detrol&reg; LA;",
"     </li>",
"     <li>",
"      Unidet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of overactive bladder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     2 mg twice daily; the dose may be lowered to 1 mg twice daily based on individual response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosing adjustment in patients concurrently taking strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir): 1 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Extended release capsule:",
"     </i>",
"     4 mg once daily; dose may be lowered to 2 mg once daily based on individual response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosing adjustment in patients concurrently taking strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir):  2 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Safety and efficacy in patients &gt;64 years was found to be similar to that in younger patients; no dosage adjustment is needed based on age.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F230072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Significantly reduced renal function (studies conducted in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute): 1 mg twice daily; use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Extended release capsule:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Use is not recommended; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F230073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Significantly reduced hepatic function: 1 mg twice daily; use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Extended release capsule:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): 2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use is not recommended; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as tartrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Detrol&reg; LA: 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Detrol&reg;: 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release capsule: Swallow whole; do not crush, chew, or open",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tolterodine may be confused with fesoterodine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Detrol&reg; may be confused with Ditropan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported with immediate release tablet, unless otherwise specified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Dry mouth (35%; extended release capsules 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7%; extended release capsules 6%), dizziness (5%; extended release capsules 2%), fatigue (4%; extended release capsules 2%), somnolence (3%; extended release capsules 3%), anxiety (extended release capsules 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dry skin (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (7%; extended release capsules 6%), abdominal pain (5%; extended release capsules 4%), diarrhea (4%), dyspepsia (4%; extended release capsules 3%), weight gain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (2%; extended release capsules 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Dry eyes (3%; extended release capsules 3%), abnormal vision (2%; extended release capsules 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (2%), sinusitis (extended release capsules 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (3%), infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, confusion, dementia aggravated, disorientation, hallucinations, memory impairment, palpitation, peripheral edema, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolterodine or fesoterodine (both are metabolized to 5-hydroxymethyl tolterodine) or any component of the formulation; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Cases of angioedema have been reported; some cases have occurred after a single dose. Discontinue immediately if angioedema and associated difficulty breathing, airway obstruction, or hypotension develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction or discontinuation should be considered if CNS effects occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: Has been associated with QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation at high (supratherapeutic) doses. The manufacturer recommends caution in patients with congenital prolonged QT or in patients receiving concurrent therapy with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs (class Ia or III antiarrhythmics). However, the extent of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation even at supratherapeutic dosages was less than 15 msec. Individuals who are CYP2D6 poor metabolizers or in the presence of inhibitors of CYP2D6 and CYP3A4 may be more likely to exhibit prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder flow obstruction: Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal obstructive disorders: Use with caution in patients with decreased GI motility or gastrointestinal obstructive disorders (ie, pyloric stenosis); may increase the risk of gastric retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Dosage adjustment is recommended in patients receiving CYP3A4 inhibitors; a lower dose of tolterodine is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Medication associated with potent anticholinergic properties which may be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tolterodine. Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: May increase the serum concentration of Tolterodine. Management: Reduce tolterodine dose to 1 mg twice daily (regular release formulation) or 2 mg daily (extended release formulation) (adult doses) and monitor for increased levels/effects of tolterodine with initiation of vinblastine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Tolterodine may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F230062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Increases bioavailability (~53% increase) of tolterodine tablets (dose adjustment not necessary); does not affect the pharmacokinetics of tolterodine extended release capsules. As a CYP3A4 inhibitor, grapefruit juice may increase the serum level and/or toxicity of tolterodine, but unlikely secondary to high oral bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort (",
"     <i>",
"      Hypericum",
"     </i>",
"     ) appears to induce CYP3A enzymes.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F230050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Detrol LA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (90): $670.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (90): $670.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Detrol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (140): $620.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (140): $636.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tolterodine Tartrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (60): $198.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $203.79",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6712929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (BUN, creatinine); hepatic function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F230052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Detrodin SR (KP);",
"     </li>",
"     <li>",
"      Detrusitol (AE, AR, AT, AU, BE, BG, BH, BR, BZ, CL, CN, CO, CR, CY, CZ, DE, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IT, JO, KW, LB, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, QA, RU, SA, SE, SG, SV, SY, TR, TW, VE, YE);",
"     </li>",
"     <li>",
"      Detrusitol Retard (DK, PT);",
"     </li>",
"     <li>",
"      Detrusitol SR (BG, CH, CO, CZ, KP, MY, NO, PE, SG, TH);",
"     </li>",
"     <li>",
"      Fluserin (UY);",
"     </li>",
"     <li>",
"      Uretol SR (KP);",
"     </li>",
"     <li>",
"      Urginol (AR);",
"     </li>",
"     <li>",
"      Uridin (TW);",
"     </li>",
"     <li>",
"      Uro-Q (KP);",
"     </li>",
"     <li>",
"      Urositol (KP);",
"     </li>",
"     <li>",
"      Urotin S SR (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolterodine is a competitive antagonist of muscarinic receptors. In animal models, tolterodine demonstrates selectivity for urinary bladder receptors over salivary receptors. Urinary bladder contraction is mediated by muscarinic receptors. Tolterodine increases residual urine volume and decreases detrusor muscle pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release tablet: Rapid; &ge;77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: V",
"     <sub>",
"      d",
"     </sub>",
"     : 113 &plusmn; 27 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;96% (primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, primarily via CYP2D6 to 5-hydroxymethyltolterodine (active) and 3A4 usually (minor pathway). In patients with a genetic deficiency of CYP2D6, metabolism via 3A4 predominates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release tablet: Increased 53% with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Extensive metabolizers: ~2 hours; Poor metabolizers: ~10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule: Extensive metabolizers: ~7 hours; Poor metabolizers: ~18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Immediate release tablet: 1-2 hours; Extended release capsule: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (77%); feces (17%); primarily as metabolites (&lt;1% unchanged drug) of which the active 5-hydroxymethyl metabolite accounts for 5% to 14% (&lt;1% in poor metabolizers); as unchanged drug (&lt;1%; &lt;2.5% in poor metabolizers)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/19/14646/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10292 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-D3B5B19E3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14646=[""].join("\n");
var outline_f14_19_14646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230100\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230070\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230071\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230072\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230073\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230044\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230030\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230046\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230045\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230107\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230098\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230049\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230034\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230094\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230039\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230062\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230041\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230051\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230075\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230050\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6712929\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230052\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230033\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230048\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10292|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/25/41364?source=related_link\">",
"      Tolterodine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/28/2502?source=related_link\">",
"      Tolterodine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_19_14647="Capillary electrophoresis of hemoglobins";
var content_f14_19_14647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Capillary electrophoresis of hemoglobin variants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 580px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Separation pattern and quantification of an artificial mixture of normal and some common variant hemoglobins by capillary electrophoresis (courtesy of Sebia&reg;). The first of the two boxed items (top) is the actual capillary electrophoretic separation pattern of the hemoglobins seen in the graph. For quantification, these are scanned at 415 nm wavelength and the relative percentage is calculated, as shown in the second (bottom) box.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14647=[""].join("\n");
var outline_f14_19_14647=null;
var title_f14_19_14648="Aminophylline: Drug information";
var content_f14_19_14648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aminophylline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/11/16564?source=see_link\">",
"    see \"Aminophylline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/47/9975?source=see_link\">",
"    see \"Aminophylline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aminophylline Injection;",
"     </li>",
"     <li>",
"      JAA-Aminophylline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase Enzyme Inhibitor, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized based on peak serum concentrations and should be based on ideal body weight. Theophylline dose is 80% of aminophylline dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute symptoms: Loading dose:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients",
"     <b>",
"      not currently receiving",
"     </b>",
"     aminophylline or theophylline: Aminophylline 5.7 mg/kg (equivalent to theophylline 4.6 mg/kg) administered I.V. or theophylline 5 mg/kg administered orally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients",
"     <b>",
"      currently receiving",
"     </b>",
"     aminophylline or theophylline: A loading dose is not recommended without first obtaining a serum theophylline concentration in patients who have received aminophylline or theophylline within the past 24 hours. The loading dose should be calculated as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V",
"     <sub>",
"      d",
"     </sub>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute symptoms:  Maintenance dose:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     To achieve a target theophylline concentration of 10 mcg/mL unless otherwise noted. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum level measurements during the first 12- to 24-hour period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults 16-60 years (otherwise healthy, nonsmokers): 0.51 mg/kg/hour (equivalent to theophylline 0.4 mg/kg/hour); maximum: 900 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults &gt;60 years: 0.38 mg/kg/hour (equivalent to theophylline 0.3 mg/kg/hour); maximum: 400 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosage adjustment for cardiac decompensation, cor pulmonale, hepatic dysfunction, sepsis with multiorgan failure, shock: 0.25 mg/kg/hour (equivalent to theophylline 0.2 mg/kg/hour); maximum: 400 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment after serum theophylline measurement:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Within normal limits:",
"     </i>",
"     Asthma: 5-15 mcg/mL: Maintain dosage if tolerated. Recheck serum theophylline concentration at 24-hour intervals (for acute I.V. dosing) or at 6- to 12-month intervals (for oral dosing). Finer adjustments in dosage may be needed for some patients. If levels &ge;15 mcg/mL, consider 10% dose reduction to improve safety margin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Too high:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-24.9 mcg/mL: Decrease dose by ~25%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-30 mcg/mL: Skip next dose (oral) or stop infusion for 12 hours (children) or 24 hours (adults) and decrease subsequent doses by ~25%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;30 mcg/mL: Stop dosing and treat overdose; if resumed, decrease subsequent doses by 50%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Too low:",
"     </i>",
"     &lt;9.9 mcg/mL: If tolerated, but symptoms remain, increase dose by ~25%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Recheck serum theophylline levels after 3 days when using oral dosing, or after 12 hours (children) or 24 hours (adults) when dosing intravenously. Patients maintained with oral therapy may be reassessed at 6- to 12-month intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Chronic conditions:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Increase dose only if tolerated. Consider lowering dose or using a slower titration if caffeine-like adverse events occur. Smaller doses given more frequently may be used in patients with a more rapid metabolism to prevent breakthrough symptoms which could occur due to low trough concentration prior to the next dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults 16-60 years",
"     <b>",
"      without",
"     </b>",
"     risk factors for impaired theophylline clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Aminophylline 380 mg/day (equivalent to theophylline 300 mg/day) in divided doses every 6-8 hours for 3 days;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Then increase to 507 mg/day (equivalent to theophylline 400 mg/day) in divided doses every 6-8 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Maintenance dose: 760 mg/day (equivalent to theophylline 600 mg/day) in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dose adjustment in patients",
"     <b>",
"      with",
"     </b>",
"     risk factors for impaired theophylline clearance and patients in whom monitoring serum theophylline levels is not feasible: Do not exceed a dose of aminophylline 507 mg/day (equivalent to theophylline 400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Reversal of adenosine-, dipyridamole-, or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing (unlabeled use):",
"     </b>",
"     I.V.: 50-250 mg administered over 30-60 seconds, repeat as necessary.",
"     <b>",
"      Note:",
"     </b>",
"     Since adenosine-induced side effects are short lived after discontinuation of the infusion, aminophylline administration is only very rarely required.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F133474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/47/9975?source=see_link\">",
"      see \"Aminophylline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized based on peak serum concentrations and should be based on ideal body weight. Theophylline dose is 80% of aminophylline dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute symptoms: Loading dose:",
"     </b>",
"     Oral, I.V.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute symptoms:  Maintenance dose:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     To achieve a target theophylline concentration of 10 mcg/mL unless otherwise noted. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum level measurements during the first 12- to 24-hour period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 6-52 weeks: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21] divided by 0.79 (equivalent to theophylline: Dose (mg/kg/hour) = [(0.008 x age in weeks) + 0.21])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-9 years: 1.01 mg/kg/hour (equivalent to theophylline 0.8 mg/kg/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 9-12 years: 0.89 mg/kg/hour (equivalent to theophylline 0.7 mg/kg/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents 12-16 years (cigarette or marijuana smokers): 0.89 mg/kg/hour (equivalent to theophylline 0.7 mg/kg/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents 12-16 years (nonsmokers): 0.63 mg/kg/hour (equivalent to theophylline 0.5 mg/kg/hour); maximum 900 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &gt;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosage adjustment for cardiac decompensation, cor pulmonale, hepatic dysfunction, sepsis with multiorgan failure, shock: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment after serum theophylline measurement:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Within normal limits:",
"     </i>",
"     Asthma: 5-15 mcg/mL: Maintain dosage if tolerated. Recheck serum theophylline concentration at 24-hour intervals (for acute I.V. dosing) or at 6- to 12-month intervals (for oral dosing). Finer adjustments in dosage may be needed for some patients. If levels &ge;15 mcg/mL, consider 10% dose reduction to improve safety margin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Too high:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-24.9 mcg/mL: Decrease dose by ~25%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-30 mcg/mL: Skip next dose (oral) or stop infusion for 12 hours and decrease subsequent doses by ~25%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;30 mcg/mL: Stop dosing and treat overdose; if resumed, decrease subsequent doses by 50%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Too low:",
"     </i>",
"     &lt;9.9 mcg/mL: If tolerated, but symptoms remain, increase dose by ~25%. Recheck serum theophylline concentrations (see \"",
"     <b>",
"      Note",
"     </b>",
"     \").",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Recheck serum theophylline levels after 3 days when using oral dosing, or after 12 hours when dosing intravenously. Patients maintained with oral therapy may be reassessed at 6- to 12-month intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Chronic conditions:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Increase dose only if tolerated. Consider lowering dose or using a slower titration if caffeine-like adverse events occur. Smaller doses given more frequently may be used in patients with a more rapid metabolism to prevent breakthrough symptoms which could occur due to low trough concentration prior to the next dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 1-15 years and &lt;45 kg",
"     <b>",
"      without",
"     </b>",
"     risk factors for impaired theophylline clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Aminophylline 15.2-17.7 mg/kg/day (equivalent to theophylline 12-14 mg/kg/day) in divided doses every 4-6 hours for 3 days (maximum daily dose: aminophylline 380 mg/day, equivalent to theophylline 300 mg/day);",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Then increase to 20.3 mg/kg/day (equivalent to theophylline 16 mg/kg/day) in divided doses every 4-6 hours for 3 days (maximum dose: aminophylline 507 mg/day, equivalent to theophylline 400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Maintenance dose: 25.3 mg/kg/day (equivalent to theophylline 20 mg/kg/day) in divided doses every 4-6 hours (maximum dose: aminophylline 760 mg/day, equivalent to theophylline 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose adjustment in patients",
"     <b>",
"      with",
"     </b>",
"     risk factors for impaired theophylline clearance and patients in whom monitoring serum theophylline levels is not feasible: Do not exceed a dose of aminophylline 20.3 mg/kg/day (equivalent to theophylline 16 mg/kg/day). (Maximum dose: Aminophylline 507 mg/day, equivalent to theophylline 400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &gt;45 kg",
"     <b>",
"      without",
"     </b>",
"     risk factors for impaired theophylline clearance: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults &gt;60 years: Refer to adult dosing. Do not exceed a dose of aminophylline 507 mg/day (equivalent to theophylline 400 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;3 months, Adolescents, and Adults: Oral, I.V.: No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, theophylline clearance is decreased &ge;50% in patients with hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); a dose reduction may be required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as dihydrate: 25 mg/mL (10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as dihydrate [preservative free]: 25 mg/mL (10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dihydrate: 100 mg [DSC], 200 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10903090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 25 mg/mL (10 mL); 50 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F133429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Loading doses should be administered I.V. over 30 minutes. Infusion rate should not exceed 21 mg/hour (equivalent to theophylline 17 mg/hour) in patients with cor pulmonale, cardiac decompensation, liver dysfunction, patients &gt;60 years of age, or patients taking medications which reduce theophylline clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     For reversal of adenosine-, dipyridamole-, or regadenoson-induced adverse events during nuclear cardiac stress testing, administer I.V. undiluted over 30-60 seconds, repeat as necessary. Since adenosine-induced side effects are short lived after discontinuation of the infusion, aminophylline administration is only very rarely required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: If dose is missed, administer the next dose at the scheduled time (do not make up missed dose).",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     250 mg in 250 mL (concentration: 1 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F133499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in D",
"     <sub>",
"      5",
"     </sub>",
"     W, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, atracurium,  aztreonam, bivalirudin, caffeine citrate, cimetidine, cladribine, clonidine, dexmedetomidine, docetaxel, doripenem, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, famotidine, filgrastim, fluconazole, fludarabine, foscarnet, gallium, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, inamrinone, labetalol, levofloxacin, linezolid, melphalan, meropenem, micafungin, morphine, oxaliplatin, paclitaxel, pancuronium, pantoprazole, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, ciprofloxacin, dobutamine, fenoldopam, hydralazine, isoproterenol, ondansetron, TrophAmine&reg;, vinorelbine, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftazidime, cisatracurium, diltiazem, methylprednisolone sodium succinate, verapamil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, heparin, metoclopramide, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone, dimenhydrinate, doxapram, potassium phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptoms and reversible airway obstruction due to asthma or other chronic lung diseases (eg, emphysema, chronic bronchitis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The National Heart, Lung, and Blood Institute Guidelines (2007) do not recommend aminophylline I.V. for the treatment of asthma exacerbations.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5584663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversal of adenosine-, dipyridamole-, or regadenoson-induced adverse reactions (eg, angina, hypotension) during nuclear cardiac stress testing",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aminophylline may be confused with amitriptyline, ampicillin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined. Adverse events observed at therapeutic serum levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flutter, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Behavior alterations (children), headache, insomnia, irritability, restlessness, seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic skin reactions, exfoliative dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to theophylline, ethylenediamine, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Coronary artery disease where cardiac stimulation might prove harmful; patients with peptic ulcer disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Theophylline toxicity: If a patient develops signs and symptoms of theophylline toxicity (eg, persistent, repetitive vomiting), a serum level should be measured and subsequent doses held. Theophylline clearance may be decreased in patients with acute pulmonary edema, congestive heart failure, cor pulmonale, fever, hepatic disease, acute hepatitis, cirrhosis, hypothyroidism, sepsis with multiorgan failure, and shock; clearance may also be decreased in neonates, infants &lt;3 months of age with decreased renal function, children &lt;1 year of age, the elderly &gt;60 years, and patients following cessation of smoking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypertension or cardiac arrhythmias (excluding bradyarrhythmias).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patient with peptic ulcer disease (use is contraindicated in the Canadian labeling).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage adjustments: Due to potential saturation of theophylline clearance at serum levels within (or in some patients less than) the therapeutic range, dosage adjustment should be made in small increments (maximum: 25% dose increase).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Due to wide interpatient variability, theophylline serum level measurements must be used to optimize therapy and prevent serious toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F133489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adalimumab: May decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives. Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated. Management: The U.S. febuxostat labeling recommends using caution in patients receiving concomitant theophylline due to risks of increased theophylline metabolite exposure. The Canadian febuxostat labeling contraindicates its use with theophylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Theophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Theophylline Derivatives may decrease the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoproterenol: May decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin; Telithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.  Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Theophylline Derivatives may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fosamprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Sparfloxacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Aminophylline may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiabendazole: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: May increase the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticlopidine: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: Theophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F133447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food does not appreciably affect absorption. Avoid extremes of dietary protein and carbohydrate intake. Changes in diet may affect the elimination of theophylline; charcoal-broiled foods may increase elimination, reducing half-life by 50%. Ethanol may decrease theophylline clearance.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Theophylline monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F133437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Theophylline monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F133435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aminophylline Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (10 mL): $0.82",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10903064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor heart rate; CNS effects (insomnia, irritability); respiratory rate (COPD patients often have resting controlled respiratory rates in low 20s); arterial or capillary blood gases (if applicable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline levels: Serum theophylline levels should be monitored prior to making dose increases; in the presence of signs or symptoms of toxicity; or when a new illness, worsening of a present illness, or medication changes occur that may change theophylline clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. loading dose: Measure serum concentrations 30 minutes after the end of an I.V. loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. infusion: Measure serum concentrations one half-life after starting a continuous infusion, then every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10903087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic levels: Asthma: 5-15 mcg/mL (peak level)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toxic concentration: &gt;20 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F133438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amilin (PH);",
"     </li>",
"     <li>",
"      Aminocont (FI);",
"     </li>",
"     <li>",
"      Aminofilina (CO, EC, GT, PL);",
"     </li>",
"     <li>",
"      Aminomal (CH, IT);",
"     </li>",
"     <li>",
"      Aminophyllin (HR, NO);",
"     </li>",
"     <li>",
"      Aminophylline Renaudin (FR);",
"     </li>",
"     <li>",
"      Aminophyllinum (PL);",
"     </li>",
"     <li>",
"      Aminophyllinum Prolongatum (PL);",
"     </li>",
"     <li>",
"      Aminophyllinum Retard (HU, PL);",
"     </li>",
"     <li>",
"      Aminoslow (LU);",
"     </li>",
"     <li>",
"      Asiphylline (TW);",
"     </li>",
"     <li>",
"      Asmafilin (TR);",
"     </li>",
"     <li>",
"      Asthcontin (KP);",
"     </li>",
"     <li>",
"      Cardiomin (CN);",
"     </li>",
"     <li>",
"      Cardirenal (AR);",
"     </li>",
"     <li>",
"      Cardophyllin (AU);",
"     </li>",
"     <li>",
"      Carine (AU);",
"     </li>",
"     <li>",
"      Clonofillin SR (HU);",
"     </li>",
"     <li>",
"      Diaphyllin (HN, HU);",
"     </li>",
"     <li>",
"      Escophyllin (CH);",
"     </li>",
"     <li>",
"      Eufilina (ES);",
"     </li>",
"     <li>",
"      Eufilina Venosa (ES);",
"     </li>",
"     <li>",
"      Euphyllin (AT, BE, CH, DE, LU, NL);",
"     </li>",
"     <li>",
"      Euphyllin Retard (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Filotempo (PT);",
"     </li>",
"     <li>",
"      Godafilin (ES);",
"     </li>",
"     <li>",
"      Minophyl (IN);",
"     </li>",
"     <li>",
"      Neophyllin (JP, SG);",
"     </li>",
"     <li>",
"      Pediatric Asthcontin for Children SR (KP);",
"     </li>",
"     <li>",
"      Peterphyllin (ZA);",
"     </li>",
"     <li>",
"      Phaminov (PH);",
"     </li>",
"     <li>",
"      Pharmafil (MX);",
"     </li>",
"     <li>",
"      Phyllocontin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, ID, IE, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PK, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Phyllocontin Continus (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Phyllotemp (CH, DE, GR);",
"     </li>",
"     <li>",
"      Planphylline (FR);",
"     </li>",
"     <li>",
"      Retafilin (HR);",
"     </li>",
"     <li>",
"      Sofafyllin (BG);",
"     </li>",
"     <li>",
"      Syntophyllin (CZ);",
"     </li>",
"     <li>",
"      Tefamin (IT);",
"     </li>",
"     <li>",
"      Teofylamin (DK);",
"     </li>",
"     <li>",
"      Teofyllamin Ipex (SE);",
"     </li>",
"     <li>",
"      Unifilin (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes bronchodilatation, diuresis, CNS and cardiac stimulation, and gastric acid secretion by blocking phosphodiesterase which increases tissue concentrations of cyclic adenine monophosphate (cAMP) which in turn promote catecholamine stimulation of lipolysis, glycogenolysis, and gluconeogenesis and induce release of epinephrine from adrenal medulla cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Theophylline:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.45 L/kg based on ideal body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Children &gt;1 year and Adults: Hepatic; involves CYP1A2, 2E1, and 3A4; forms active metabolites (caffeine and 3-methylxanthine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Highly variable and dependent upon age, liver function, cardiac function, lung disease, and smoking history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature infants, postnatal age 3-15 days: 30 hours (range: 17-43 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature infants, postnatal age 25-57 days: 20 hours (range: 9.4-30.6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-4 yrs: 3.4 hours (range: 1.2-5.6 hours); 6-17 years: 3.7 hours (range: 1.5-5.9 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults 16-60 years with asthma, nonsmoking, otherwise healthy: 8.7 hours (range: 6.1-12.8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Children &gt;3 months and Adults: Urine (10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Society of Nuclear Cardiology, &ldquo;Imaging Guidelines for Nuclear Cardiology Procedures: A Report of The American Society of Nuclear Cardiology Quality Assurance Committee,&rdquo;",
"      <i>",
"       J  Nucl Cardiol",
"      </i>",
"      , 2006, 13(6):e21-171.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cummins LH, et al, &ldquo;Erythromycin's Effect on Theophylline Blood Levels. Correspondence,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1977, 59:144-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delaforge M and Sartori E, &ldquo;",
"      <i>",
"       In Vivo",
"      </i>",
"      Effects of Erythromycin, Oleandomycin, and Erythralosamine Derivatives on Hepatic Cytochrome P450,&rdquo;",
"      <i>",
"       Biochem Pharmacol",
"      </i>",
"      , 1990, 40(2):223-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/19/14648/abstract-text/2375764/pubmed\" id=\"2375764\" target=\"_blank\">",
"        2375764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Homma S, Gilliland Y, Guiney TE, et al,&ldquo;Safety of Intravenous Dipyridamole for Stress Testing With Thallium Imaging,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1987, 59(1):152-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/19/14648/abstract-text/3812227/pubmed\" id=\"3812227\" target=\"_blank\">",
"        3812227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klocke FJ, Baird MG, Lorell BH, et al, &ldquo;ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 42(7):1318-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/19/14648/abstract-text/14522503/pubmed\" id=\"14522503\" target=\"_blank\">",
"        14522503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ludden TM, &ldquo;Pharmacokinetic Interactions of the Macrolide Antibiotics,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 10(1):63-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/19/14648/abstract-text/3882305/pubmed\" id=\"3882305\" target=\"_blank\">",
"        3882305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ranhosky A and Kempthorne-Rawson J, &ldquo;The Safety of Intravenous Dipyridamole Thallium Myocardial Perfusion Imaging. Intravenous Dipyridamole Thallium Imaging Study Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1990, 81(4):1205-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/19/14648/abstract-text/2107985/pubmed\" id=\"2107985\" target=\"_blank\">",
"        2107985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8620 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14648=[""].join("\n");
var outline_f14_19_14648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133450\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133493\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133454\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133474\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133455\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682648\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682649\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133426\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10903090\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133412\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133429\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471280\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471281\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133499\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133427\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5584663\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133500\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133491\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133432\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133416\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133489\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133420\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133447\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133422\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133436\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133458\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133437\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133435\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10903064\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10903087\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133438\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133415\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133431\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8620|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/11/16564?source=related_link\">",
"      Aminophylline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/47/9975?source=related_link\">",
"      Aminophylline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_19_14649="Microbiology and epidemiology of salmonellosis";
var content_f14_19_14649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and epidemiology of salmonellosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/19/14649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/19/14649/contributors\">",
"     Elizabeth L Hohmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/19/14649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/19/14649/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/19/14649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/19/14649/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/19/14649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salmonellae are motile gram-negative bacilli that infect or colonize a wide range of mammalian hosts. They cause a number of characteristic clinical infections in humans, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastroenteritis",
"     </li>",
"     <li>",
"      Enteric fever (systemic illness with fever and abdominal symptoms)",
"     </li>",
"     <li>",
"      Bacteremia and endovascular infection",
"     </li>",
"     <li>",
"      Focal metastatic infections such as osteomyelitis or abscess",
"     </li>",
"     <li>",
"      An asymptomatic chronic carrier state",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The bacteriology, epidemiology, and trends in antimicrobial resistance of these organisms will be reviewed here. The pathogenesis, clinical description, and treatment of specific Salmonella syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19033?source=see_link\">",
"     \"Pathogenesis of Salmonella gastroenteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=see_link\">",
"     \"Pathogenesis of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACTERIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Salmonella consists of two species, Salmonella enterica and Salmonella bongori; the former is further divided into six different subspecies. Based upon high levels of DNA similarity, most clinically important Salmonellae are formally classified within a single subspecies, Salmonella enterica, subspecies enterica [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/1\">",
"     1",
"    </a>",
"    ]. Familiar organisms such as Salmonella typhi, Salmonella choleraesuis, and Salmonella enteritidis, previously believed to represent separate species based upon antigenic structures, host range, and biochemical characteristics, are now individual serotypes of this single subspecies. Many laboratories will continue to report names recognizable to clinicians such as: Salmonella Typhimurium or Salmonella enterica serovar Typhi. Serotype and serovar are synonymous.",
"   </p>",
"   <p>",
"    Salmonella are relatively easy to identify in the clinical microbiology laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/2\">",
"     2",
"    </a>",
"    ]. Salmonellae grow under both aerobic and anaerobic conditions. Salmonella are oxidase negative and virtually all are lactose negative (white on MacConkey agar plates); most Salmonellae produce hydrogen sulfide, which is easily detected on selective indicator plates such as Hektoen, or Salmonella-Shigella agar, which are used for plating stool specimens.",
"   </p>",
"   <p>",
"    Most laboratories identify Salmonellae by a combination of antigenic and biochemical reactions. Suspicious colonies are agglutinated using antisera directed against specific O (lipopolysaccharide) and H (flagellar) antigens that allow identification of the serogroup. Only S. typhi, S. paratyphi C, and some strains of Salmonella dublin and Citrobacter freundii possess the Vi capsular polysaccharide antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/3\">",
"     3",
"    </a>",
"    ], which can be rapidly detected by slide agglutination studies.",
"   </p>",
"   <p>",
"    Although serogrouping may provide a clue as to the specific organism (",
"    <a class=\"graphic graphic_table graphicRef81462 \" href=\"UTD.htm?4/6/4204\">",
"     table 1",
"    </a>",
"    ), this may not always be useful clinically. As an example, both S. enteritidis (which most frequently causes gastroenteritis) and S. typhi (which causes enteric fever) belong to group D; S. enteritidis may occasionally cause a systemic \"typhoidal\" illness with bacteremia. Formal serotyping is more specific than serogrouping and usually is only performed at state or reference laboratories.",
"   </p>",
"   <p>",
"    Some have advocated the use of typing techniques such as pulsed-field gel electrophoresis on strains of S. enterica serotype typhimurium to detect outbreaks that might otherwise be missed. The Minnesota Department of Health adopted such an approach and identified 16 outbreaks accounting for 154 of 958 isolates between 1994 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/4\">",
"     4",
"    </a>",
"    ]. Twenty-seven percent of isolates were resistant to at least five antibiotics when sensitivity testing was performed; the multidrug resistant strains all had unique pulsed-field gel electrophoresis patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoidal and nontyphoidal Salmonella infections are quite different in their epidemiology. The former are usually acquired abroad whereas the latter are most often domestically acquired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Salmonella typhi and Salmonella paratyphi",
"    </span>",
"    &nbsp;&mdash;&nbsp;These organisms, which cause typhoid fever, have a high host specificity for humans. Infection virtually always implies contact with an acutely infected individual, a chronic carrier, or contaminated food and water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=see_link\">",
"     \"Pathogenesis of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typhoid fever remains a global health problem, with an estimated 21.6 million illnesses and 216,500 deaths worldwide in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence was high (&gt;100 cases per 100,000 population per year) in south-central Asia, Southeast Asia, and southern Africa; medium (10 to 100 cases per 100,000) in the rest of Asia, Africa, Latin America, and Oceania, except for Australia and New Zealand; and low in the other parts of the world (&lt;10 cases per 100,000).",
"   </p>",
"   <p>",
"    Paratyphoid fever was estimated to have caused 5.4 million illnesses in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/5\">",
"     5",
"    </a>",
"    ]. The proportion of cases due to S. paratyphi is increasing in some areas, including Nepal (34 percent of isolates from 1999 to 2003, up from 23 percent in the mid-1990s) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvements in food handling, waste management, and water treatment are clearly the most important means of controlling typhoid fever and other enteric pathogens.",
"   </p>",
"   <p>",
"    In the United States, typhoid fever has become less prevalent and is now primarily a disease of travelers and immigrants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of laboratory-confirmed cases reported to the Centers for Disease Control and Prevention (CDC) between 1999 and 2006, there were about 1900 cases of S. typhi infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/7\">",
"       7",
"      </a>",
"      ]. Nearly 80 percent were associated with travel, and only 5 percent of those reporting immunizations had received a typhoid fever vaccine. Four countries accounted for most travel-associated cases: India (47 percent), Pakistan, Bangladesh, and Mexico.",
"     </li>",
"     <li>",
"      The risk of travel to the Indian subcontinent (estimated rate &gt;100 cases per million travelers), or Southeast Asia and Africa (estimated 5 to 14 cases per million travelers) is significantly higher [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Travelers to these and other high-risk endemic areas should be vaccinated with either the live oral attenuated vaccine Ty21a or the Vi capsular polysaccharide vaccine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"       \"Immunizations for travel\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, domestically acquired typhoid fever may be related to chronic carriers, but the source of sporadic cases frequently remains enigmatic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/9\">",
"     9",
"    </a>",
"    ]. Outbreaks have been described related to contaminated water supplies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/10\">",
"     10",
"    </a>",
"    ], specific foods consumed at social gatherings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], unappreciated chronic carriers working in the food service industry [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/13\">",
"     13",
"    </a>",
"    ], and close personal contact in a psychiatric institution [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nontyphoidal Salmonellae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike infection with typhoidal Salmonellae, nontyphoidal salmonellosis increased steadily in the United States from World War II through the 1980s (",
"    <a class=\"graphic graphic_figure graphicRef79532 \" href=\"UTD.htm?39/22/40301\">",
"     figure 1",
"    </a>",
"    ). A substantial decline in nontyphoidal salmonellosis began in the mid-1990s, but cases increased again in the late 2000s [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/15\">",
"     15",
"    </a>",
"    ]. S. enteritidis, S. newport, and S. typhimurium are now the serotypes most frequently isolated in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/16\">",
"     16",
"    </a>",
"    ]. During 2003, a total of 43,657 cases of salmonellosis were reported in the United States, of which 40 percent occurred among children aged &lt;15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/17\">",
"     17",
"    </a>",
"    ]. These numbers represent a fraction of the true incidence, as many cases are not diagnosed. There are an estimated 39 cases of undocumented salmonellosis for each culture-confirmed case [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/18\">",
"     18",
"    </a>",
"    ]. The global burden of nontyphoidal Salmonella gastroenteritis has been estimated at about 94 million cases (mostly foodborne) and 155,000 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Foodborne infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontyphoidal Salmonellae are associated with animal reservoirs and therefore with agricultural products, especially eggs and poultry [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Among 6647 outbreaks of foodborne disease reported to the CDC between 1998 and 2002, S. enteritidis accounted for the largest number of outbreaks and outbreak-related cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/23\">",
"     23",
"    </a>",
"    ]. The majority of S. enteritidis outbreaks were related to eggs.",
"   </p>",
"   <p>",
"    Salmonellae can be passed transovarially from chickens to intact shell eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, single, intact, normal-appearing eggs can transmit infection. The frequency of S. enteritidis-contaminated eggs is difficult to estimate because the rate varies depending upon the level of colonization among hens in a flock and the timing of egg production with respect to acquisition of infection in the hen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/21\">",
"     21",
"    </a>",
"    ]. On average, in the United States, the frequency of contamination is one in 20,000 eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pooling of large numbers of eggs can result in contamination of food products that may be distributed nationally and potentially transmit infection to thousands. As an example, a nationwide outbreak of 224,000 cases of S. enteritidis infection resulted from ice cream manufactured in one state and distributed widely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/26\">",
"     26",
"    </a>",
"    ]. The putative source of contamination was tankers, which transported ice cream base but previously had been used to carry liquid eggs.",
"   </p>",
"   <p>",
"    Peanut butter containing products contaminated with S. typhimurium were implicated in 2008-2009 as the cause of illness in 529 persons from 43 states [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The contamination was traced to a Georgia plant and many products were recalled.",
"   </p>",
"   <p>",
"    Nontyphoidal Salmonellae have also been associated with fresh produce, meat (including ground beef as well as dog food), milk, spices, and other foods (",
"    <a class=\"graphic graphic_table graphicRef75035 \" href=\"UTD.htm?39/10/40107\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/29-41\">",
"     29-41",
"    </a>",
"    ]. Contamination can occur at many points along the food processing pathway, which, in developed countries, has become increasingly industrialized, centralized, and global in scope.",
"   </p>",
"   <p>",
"    Patients with foodborne salmonellosis may have more severe disease than with other foodborne infections. This was suggested in a registry-based study from Denmark that included 52,121 patients with foodborne bacterial gastroenteritis: 18 percent had infection due to nontyphoidal Salmonella spp, and 14 percent were hospitalized within 90 days of a microbiologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk of invasive illness was more than sixfold higher in patients with infection due to nontyphoidal Salmonella compared with other bacterial causes of gastroenteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18576815\">",
"    <span class=\"h4\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;FoodNet is a collaborative active surveillance program involving 10 state public health departments, the CDC, FDA, and Department of Agriculture, which now surveys approximately 15 percent of the United States population for foodborne illnesses. FoodNet began in 1996; the following observations since that time have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conservative estimates indicated that there were about 1.4 million Salmonella infections in the United States, which resulted in about 15,000 hospitalizations and approximately 400 deaths per year [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nontyphoidal Salmonella infections proportionally cause the greatest percentage of hospitalizations and deaths due to foodborne pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salmonellosis is most problematic in people over 60 and infants. Most deaths occurred in older patients with comorbid illnesses. Seventy-one percent of patients with invasive salmonellosis were hospitalized and approximately 5 percent died [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case control studies in infants strongly suggested that breast feeding protects against acquisition of Salmonella infection in infancy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Other independent studies show that risks for salmonellosis in infants include riding in a shopping cart with meat or poultry placed next to them and ingestion of concentrated liquid infant formula, perhaps related to the storage and handling of opened cans of concentrated formula [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/46\">",
"       46",
"      </a>",
"      ]; outbreaks of salmonellosis also have been linked to consumption of powdered infant formula [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chicken consumption (not just egg consumption) appeared to be a new risk factor for development of Salmonella enteritidis infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salmonellosis rates differed by region. A decrease in rate was seen and in some areas may have been due to on-farm control measures, better refrigeration, consumer education, and better food handling in restaurants and homes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/51\">",
"       51",
"      </a>",
"      ]. However, not all sites had lower rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From 1996 to 1999, overall cases of salmonellosis decreased in FoodNet sites (including Minnesota, Oregon, California, Connecticut and Georgia). The decline in salmonellosis continued through 2003 (13.5 versus 14.5 cases per 100,000 in 1996-1998) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/52\">",
"     52",
"    </a>",
"    ], and was due to a reduction in S. typhimurium infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, rates of salmonellosis, driven partly by increases in infections with S. enteritidis and S. newport, subsequently rebounded to 17.6 cases per 100,000 persons in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/15,54\">",
"     15,54",
"    </a>",
"    ]. Salmonella remains the most common isolated pathogen of those evaluated in the FoodNet survey, accounting for 43 percent of cases in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salmonella outbreaks due to multiple serotypes may occur more frequently than recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/55\">",
"     55",
"    </a>",
"    ]. Because certain serotypes are known to be likely associated with particular food types or animal sources, evaluating for the presence of multiple serotypes (if resources permit) can help focus the investigation on potential outbreak sources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other methods of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to foodborne outbreaks, transmission of Salmonella can occur in day care settings from pet reptiles and amphibians (eg, snakes, lizards, turtles, iguanas, frogs) in infants and preschool-aged children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/46,56-60\">",
"     46,56-60",
"    </a>",
"    ], from live poultry including chicks and ducklings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], from pets (hamsters, mice, rats, and hedgehogs) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/63-65\">",
"     63-65",
"    </a>",
"    ], from cats and dogs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/66\">",
"     66",
"    </a>",
"    ], contaminated marijuana [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/67\">",
"     67",
"    </a>",
"    ], and pet foods [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case-control study conducted in 1996 and 1997 in five states in the United States estimated that reptiles and amphibians accounted for 6 percent of all human, laboratory-confirmed sporadic Salmonella infections, and 21 percent in individuals under age 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/70\">",
"     70",
"    </a>",
"    ]. In a subsequent report from Michigan, reptile-associated salmonellosis accounted for 12 percent of cases of Salmonella infection in children &le;5 years of age between January 2001 and June 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/57\">",
"     57",
"    </a>",
"    ]. Turtles were considered the probable source of many of these infections. However, since nontyphoidal Salmonella infections are common and usually sporadic, the association with turtle exposure may not be detected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control (CDC) in the United States recommends that children under five years of age and immunocompromised patients avoid contact with reptiles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/58,71,72\">",
"     58,71,72",
"    </a>",
"    ]. Although there is a federal law prohibiting the sale of small turtles, turtle sales continue to occur. The risk of Salmonella infection after reptile exposure can be reduced by washing hands with soap and water after handling reptiles and keeping the reptiles away from food-preparation areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/59\">",
"     59",
"    </a>",
"    ]. CDC recommendations for turtles as pets are available at:",
"    <a class=\"external\" href=\"file://www.cdc.gov/healthypets/spotlight_an_turtles.htm\">",
"     file://www.cdc.gov/healthypets/spotlight_an_turtles.htm",
"    </a>",
"   </p>",
"   <p>",
"    Live poultry are a source of Salmonella infection that is relatively under-recognized by the general public. Between 2004 and 2011, 316 illnesses caused by a particular strain of S. montevideo were reported from multiple states across the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/62\">",
"     62",
"    </a>",
"    ]. The majority of patients were children younger than five years old, and most reported contact with live young poultry, many of which had been purchased as pets, in the week prior to the illness. Of those interviewed, only 21 percent were aware of the risk of Salmonella with the handling of live poultry, and only 7 percent were apprised of this risk on acquisition of the bird. Investigation traced the outbreak to a mail-order hatchery, which subsequently instituted control measures that decreased but did not eliminate the number of cases caused by this strain of S. montevideo in subsequent years. Smaller outbreaks of different Salmonella species have been also been linked to handling of live poultry purchased as pets or for backyard flocks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/61,73,74\">",
"     61,73,74",
"    </a>",
"    ]. The potential impact of this risk is quite large, as approximately 50 million live poultry are sold through mail-order hatcheries in the United States annually. The Centers for Disease Control and Prevention (CDC) in the United States recommends that live poultry should not be kept inside the house, particularly in areas where food or drink is prepared or served. Hands should be washed with soap and water after touching live poultry or their environment, and children under five years of age and immunocompromised patients should avoid handling live poultry, including chicks and ducks.",
"   </p>",
"   <p>",
"    Although other pets are rarely confirmed as the source of human salmonellosis, zoonotic transmission of gastrointestinal illnesses from sick pets may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/63,64,66\">",
"     63,64,66",
"    </a>",
"    ]. Raw pet foods and treats for companion animals may also be a hidden reservoir of Salmonella in the home [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to infection from pets, there have been multiple outbreaks of enteric disease associated with animal exposure in public settings, such as county fairs, farms, and petting zoos. In a review of 55 such outbreaks, Salmonella species accounted for 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An outbreak of fluoroquinolone-resistant salmonellosis, in which the presumed mechanism of spread was person-to-person or via contact with contaminated surfaces, has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Antimicrobial Resistance Monitoring Systems (NARMS): Enteric Bacteria is a collaboration among the CDC, United States Food and Drug Administration (FDA), and United States Department of Agriculture (USDA) that monitors antimicrobial resistance in enteric bacteria, including Salmonella spp [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/79\">",
"     79",
"    </a>",
"    ]. The website has the most currently available information on resistance reports in the United States (",
"    <a class=\"external\" href=\"file://www.cdc.gov/narms/\">",
"     www.cdc.gov/narms/",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Salmonella typhi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 1989, Salmonella typhi resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , and sulfonamides (ie, multidrug-resistant or MDR strains) have become a worldwide problem [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/80\">",
"     80",
"    </a>",
"    ], necessitating the use of newer antimicrobials such as the fluoroquinolones and third generation cephalosporins for therapy of typhoid fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    .) However, the appearance of fluoroquinolone-resistant strains of S. typhi in Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/81\">",
"     81",
"    </a>",
"    ] and India [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/82,83\">",
"     82,83",
"    </a>",
"    ] represents a new obstacle for clinicians in endemic areas in which rapidly effective oral agents are needed for the treatment of typhoid fever. Nalidixic acid resistance among S. typhi isolates in Asia increased from 5 to 50 percent between 1993 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2007, 62 percent of all US isolates were resistant to nalidixic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/79\">",
"     79",
"    </a>",
"    ]. Approximately 88 percent of US cases imported from India between 1999 and 2006 were nalidixic acid resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/7\">",
"     7",
"    </a>",
"    ]. Another report from central India noted that 98 percent of isolates were nalidixic acid resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/85\">",
"     85",
"    </a>",
"    ]. Full resistance to fluoroquinolones (MIC &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    in both S. typhi and S. paratyphi is less common but increasing worldwide. A compilation of studies showed rates of fully quinolone-resistant organisms ranged from 0 to 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/86\">",
"     86",
"    </a>",
"    ]. Ceftriaxone-resistant S. typhi or S. paratyphi does not yet appear to have emerged, but routine use of this drug in resource poor areas is limited by cost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nontyphoidal Salmonella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial resistance is a global problem with nontyphoidal Salmonellae [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. There is significant geographic variability, and epidemics of specific problematic strains occur worldwide. In the United States, data on nontyphoidal Salmonella isolates collected by the CDC showed that the prevalence of S. typhimurium isolates with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , sulfonamides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    increased between 1979 and 1996 from 0.6 to 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/89\">",
"     89",
"    </a>",
"    ]. Many isolates with this resistance pattern were Salmonella typhimurium definitive phage type 104 (DT104), a virulent epidemic strain had become widespread in the United Kingdom earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/90\">",
"     90",
"    </a>",
"    ], though a report from the European Enter-net International Surveillance network notes the decline of DT104 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/91\">",
"     91",
"    </a>",
"    ]. Clinically important trends include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About 2.2 percent of nontyphoidal strains in the United States are nalidixic acid resistant [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/79\">",
"       79",
"      </a>",
"      ]; in Europe this number is 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United States about 3.3 percent of nontyphoidal strains were resistant to ceftiofur, a veterinary third generation cephalosporin; resistance to this agent often correlates with decreased susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      . Europe reports 0.7 percent resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extended-spectrum beta-lactamase (ESBL) genes are emerging in Salmonellae in all areas, and certain serotypes may be more likely to support specific plasmids or resistance-encoding genetic elements [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. The Clinical and Laboratory Standards Institute has altered break points that define susceptibility of Enterobacteriaceae (including Salmonellae) to third generation cephalosporins, in part to simplify recognition of strains potentially bearing beta-lactamase resistance elements by non-reference laboratories that do not routinely perform more sophisticated testing directed at identifying these enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/95\">",
"     95",
"    </a>",
"    ]. The revised breakpoints eliminate the need to perform ESBL screen and confirmatory tests for treatment decisions. Laboratories are implementing these changes slowly, so reports may have varying definitions of resistance to these important clinical agents.",
"   </p>",
"   <p>",
"    Several reports highlight the transmission of antibiotic-resistant strains of Salmonella from food animals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from Denmark linked transmission of S. typhimurium DT104 infections in 25 patients to a Danish swine herd [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/96\">",
"       96",
"      </a>",
"      ]. Eleven patients were hospitalized, two died, and the organism had reduced susceptibility to fluoroquinolones. Other reports confirm emergence of fluoroquinolone resistance among nontyphoidal isolates [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/97,98\">",
"       97,98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from Canada described a strong correlation between ceftiofur resistance in Salmonella Heidelberg isolated from retail chicken and the incidence of ceftiofur resistance in clinical isolates from across Canada [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14649/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data highlight the need for judicious use of antimicrobial agents in both clinical practice and animal husbandry, as well as the need for ongoing surveillance of antimicrobial resistance patterns of important foodborne pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19743159\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salmonellae are motile gram-negative bacilli that typically are oxidase- and lactose-negative and produce hydrogen sulfide. Most clinically important Salmonellae are classified as Salmonella enterica, subspecies enterica. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bacteriology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Salmonellae typhi and paratyphi cause enteric fever, which has a high incidence in south-central and Southeast Asia as well as southern Africa but is uncommon in developed nations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Salmonella typhi and Salmonella paratyphi'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nontyphoidal salmonellae are common causes of foodborne gastroenteritis worldwide, particularly in outbreak settings. Eggs are a frequent vehicle for Salmonella infection since the organism can be passed transovarially from the chicken to intact, normal-appearing eggs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Foodborne infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contact with reptiles and live poultry is an additional source of Salmonella infection and should be avoided by children younger than five years and immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other methods of transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased susceptibility to fluoroquinolones in Salmonellae typhi and paratyphi is a global problem.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      resistance has not yet developed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Antimicrobial resistance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment and prevention of typhoid fever\", section on 'Antibiotic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is significant geographic variability in antimicrobial resistance patterns in nontyphoidal Salmonellae. Extended-spectrum beta-lactamase (ESBL) genes are emerging in Salmonellae in some regions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nontyphoidal Salmonella'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/1\">",
"      Tindall BJ, Grimont PA, Garrity GM, Euz&eacute;by JP. Nomenclature and taxonomy of the genus Salmonella. Int J Syst Evol Microbiol 2005; 55:521.",
"     </a>",
"    </li>",
"    <li>",
"     Farmer JJ. Enterobacteriacea: Introduction and Identification. In: Manual of Clinical Microbiology, Murray PR, et al (Eds), ASM Press, Washington, DC 1995. p.438.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/3\">",
"      Hashimoto Y, Itho Y, Fujinaga Y, et al. Development of nested PCR based on the ViaB sequence to detect Salmonella typhi. J Clin Microbiol 1995; 33:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/4\">",
"      Bender JB, Hedberg CW, Boxrud DJ, et al. Use of molecular subtyping in surveillance for Salmonella enterica serotype typhimurium. N Engl J Med 2001; 344:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/5\">",
"      Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005; 366:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/6\">",
"      Maskey AP, Basnyat B, Thwaites GE, et al. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg 2008; 102:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/7\">",
"      Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/8\">",
"      Ryan CA, Hargrett-Bean NT, Blake PA. Salmonella typhi infections in the United States, 1975-1984: increasing role of foreign travel. Rev Infect Dis 1989; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/9\">",
"      Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/10\">",
"      Mermin JH, Villar R, Carpenter J, et al. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J Infect Dis 1999; 179:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/11\">",
"      Birkhead GS, Morse DL, Levine WC, et al. Typhoid fever at a resort hotel in New York: a large outbreak with an unusual vehicle. J Infect Dis 1993; 167:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/12\">",
"      Cot&eacute; TR, Convery H, Robinson D, et al. Typhoid fever in the park: epidemiology of an outbreak at a cultural interface. J Community Health 1995; 20:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/13\">",
"      Xercavins M, Llovet T, Navarro F, et al. Epidemiology of an unusually prolonged outbreak of typhoid fever in Terrassa, Spain. Clin Infect Dis 1997; 24:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/14\">",
"      Goh KT, Teo SH, Tay L, Monteiro EH. Epidemiology and control of an outbreak of typhoid in a psychiatric institution. Epidemiol Infect 1992; 108:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: incidence and trends of infection with pathogens transmitted commonly through food--foodborne diseases active surveillance network, 10 U.S. sites, 1996-2010. MMWR Morb Mortal Wkly Rep 2011; 60:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food - 10 states, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/17\">",
"      Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases--United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/18\">",
"      Voetsch AC, Van Gilder TJ, Angulo FJ, et al. FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis 2004; 38 Suppl 3:S127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/19\">",
"      Majowicz SE, Musto J, Scallan E, et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 2010; 50:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/20\">",
"      Mishu B, Koehler J, Lee LA, et al. Outbreaks of Salmonella enteritidis infections in the United States, 1985-1991. J Infect Dis 1994; 169:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/21\">",
"      Braden CR. Salmonella enterica serotype Enteritidis and eggs: a national epidemic in the United States. Clin Infect Dis 2006; 43:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/22\">",
"      Marcus R, Varma JK, Medus C, et al. Re-assessment of risk factors for sporadic Salmonella serotype Enteritidis infections: a case-control study in five FoodNet Sites, 2002-2003. Epidemiol Infect 2007; 135:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/23\">",
"      Lynch M, Painter J, Woodruff R, et al. Surveillance for foodborne-disease outbreaks--United States, 1998-2002. MMWR Surveill Summ 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/24\">",
"      Snoeyenbos GH, Smyser CF, Van Roekel H. Salmonella infections of the ovary and peritoneum of chickens. Avian Dis 1969; 13:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/25\">",
"      Ebel E, Schlosser W. Estimating the annual fraction of eggs contaminated with Salmonella enteritidis in the United States. Int J Food Microbiol 2000; 61:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/26\">",
"      Hennessy TW, Hedberg CW, Slutsker L, et al. A national outbreak of Salmonella enteritidis infections from ice cream. The Investigation Team. N Engl J Med 1996; 334:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of Salmonella infections associated with peanut butter and peanut butter-containing products--United States, 2008-2009. MMWR Morb Mortal Wkly Rep 2009; 58:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/28\">",
"      Cavallaro E, Date K, Medus C, et al. Salmonella typhimurium infections associated with peanut products. N Engl J Med 2011; 365:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/29\">",
"      Centers for Disease Control (CDC). Multistate outbreak of Salmonella poona infections--United States and Canada, 1991. MMWR Morb Mortal Wkly Rep 1991; 40:549.",
"     </a>",
"    </li>",
"    <li>",
"     Wood RC, Hedberg C, White K, et al. A multi-state outbreak of Salmonella javiana associated with raw tomatoes (abstract). In: CDC Epidemic Intelligence Service, 40th Annual Conference, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/31\">",
"      Centers for Disease Control (CDC). Salmonella dublin and raw milk consumption--California. MMWR Morb Mortal Wkly Rep 1984; 33:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/32\">",
"      Ryan CA, Nickels MK, Hargrett-Bean NT, et al. Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. JAMA 1987; 258:3269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of Salmonella infections associated with eating Roma tomatoes--United States and Canada, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of Salmonella typhimurium infections associated with eating ground beef--United States, 2004. MMWR Morb Mortal Wkly Rep 2006; 55:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreaks of Salmonella infections associated with raw tomatoes eaten in restaurants--United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2007; 56:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Salmonella typhimurium infection associated with raw milk and cheese consumption--Pennsylvania, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of human Salmonella infections caused by contaminated dry dog food--United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2008; 57:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of Salmonella serotype Saintpaul infections associated with multiple raw produce items--United States, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/39\">",
"      Jain S, Bidol SA, Austin JL, et al. Multistate outbreak of Salmonella Typhimurium and Saintpaul infections associated with unpasteurized orange juice--United States, 2005. Clin Infect Dis 2009; 48:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/40\">",
"      Centers for Disease Control and Prevention (CDC). Salmonella montevideo infections associated with salami products made with contaminated imported black and red pepper --- United States, July 2009-April 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/41\">",
"      Barton Behravesh C, Mody RK, Jungk J, et al. 2008 outbreak of Salmonella Saintpaul infections associated with raw produce. N Engl J Med 2011; 364:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/42\">",
"      Helms M, Simonsen J, M&oslash;lbak K. Foodborne bacterial infection and hospitalization: a registry-based study. Clin Infect Dis 2006; 42:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/43\">",
"      Kennedy M, Villar R, Vugia DJ, et al. Hospitalizations and deaths due to Salmonella infections, FoodNet, 1996-1999. Clin Infect Dis 2004; 38 Suppl 3:S142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/44\">",
"      Vugia DJ, Samuel M, Farley MM, et al. Invasive Salmonella infections in the United States, FoodNet, 1996-1999: incidence, serotype distribution, and outcome. Clin Infect Dis 2004; 38 Suppl 3:S149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/45\">",
"      Rowe SY, Rocourt JR, Shiferaw B, et al. Breast-feeding decreases the risk of sporadic salmonellosis among infants in FoodNet sites. Clin Infect Dis 2004; 38 Suppl 3:S262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/46\">",
"      Jones TF, Ingram LA, Fullerton KE, et al. A case-control study of the epidemiology of sporadic Salmonella infection in infants. Pediatrics 2006; 118:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/47\">",
"      Brouard C, Espi&eacute; E, Weill FX, et al. Two consecutive large outbreaks of Salmonella enterica serotype Agona infections in infants linked to the consumption of powdered infant formula. Pediatr Infect Dis J 2007; 26:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/48\">",
"      Cahill SM, Wachsmuth IK, Costarrica Mde L, Ben Embarek PK. Powdered infant formula as a source of Salmonella infection in infants. Clin Infect Dis 2008; 46:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/49\">",
"      Kimura AC, Reddy V, Marcus R, et al. Chicken consumption is a newly identified risk factor for sporadic Salmonella enterica serotype Enteritidis infections in the United States: a case-control study in FoodNet sites. Clin Infect Dis 2004; 38 Suppl 3:S244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/50\">",
"      Altekruse SF, Bauer N, Chanlongbutra A, et al. Salmonella enteritidis in broiler chickens, United States, 2000-2005. Emerg Infect Dis 2006; 12:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/51\">",
"      Marcus R, Rabatsky-Ehr T, Mohle-Boetani JC, et al. Dramatic decrease in the incidence of Salmonella serotype Enteritidis infections in 5 FoodNet sites: 1996-1999. Clin Infect Dis 2004; 38 Suppl 3:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--selected sites, United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 States, United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/54\">",
"      Chai SJ, White PL, Lathrop SL, et al. Salmonella enterica serotype Enteritidis: increasing incidence of domestically acquired infections. Clin Infect Dis 2012; 54 Suppl 5:S488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Multiple-serotype Salmonella gastroenteritis outbreak after a reception --- Connecticut, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/56\">",
"      Harris JR, Neil KP, Behravesh CB, et al. Recent multistate outbreaks of human salmonella infections acquired from turtles: a continuing public health challenge. Clin Infect Dis 2010; 50:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/57\">",
"      Wells EV, Boulton M, Hall W, Bidol SA. Reptile-associated salmonellosis in preschool-aged children in Michigan, January 2001-June 2003. Clin Infect Dis 2004; 39:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/58\">",
"      Centers for Disease Control and Prevention (CDC). Reptile-associated salmonellosis--selected states, 1998-2002. MMWR Morb Mortal Wkly Rep 2003; 52:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC). Turtle-associated salmonellosis in humans--United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/60\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of human Salmonella typhimurium infections associated with aquatic frogs - United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 58:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/61\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: multistate outbreak of Salmonella Altona and Johannesburg infections linked to chicks and ducklings from a mail-order hatchery - United States, February-October 2011. MMWR Morb Mortal Wkly Rep 2012; 61:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/62\">",
"      Gaffga NH, Barton Behravesh C, Ettestad PJ, et al. Outbreak of salmonellosis linked to live poultry from a mail-order hatchery. N Engl J Med 2012; 366:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/63\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of multidrug-resistant Salmonella typhimurium associated with rodents purchased at retail pet stores--United States, December 2003-October 2004. MMWR Morb Mortal Wkly Rep 2005; 54:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/64\">",
"      Swanson SJ, Snider C, Braden CR, et al. Multidrug-resistant Salmonella enterica serotype Typhimurium associated with pet rodents. N Engl J Med 2007; 356:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/65\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Multistate outbreak of human Salmonella typhimurium infections linked to contact with pet hedgehogs - United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013; 62:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/66\">",
"      Cherry B, Burns A, Johnson GS, et al. Salmonella Typhimurium outbreak associated with veterinary clinic. Emerg Infect Dis 2004; 10:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/67\">",
"      Taylor DN, Wachsmuth IK, Shangkuan YH, et al. Salmonellosis associated with marijuana: a multistate outbreak traced by plasmid fingerprinting. N Engl J Med 1982; 306:1249.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/salmonella/dog-food-05-12/index.html (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Human Salmonella infantis infections linked to dry dog food--United States and Canada, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/70\">",
"      Mermin J, Hutwagner L, Vugia D, et al. Reptiles, amphibians, and human Salmonella infection: a population-based, case-control study. Clin Infect Dis 2004; 38 Suppl 3:S253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/71\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of human Salmonella typhimurium infections associated with pet turtle exposure - United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/72\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: outbreak of salmonellosis associated with pet turtle exposures--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:79.",
"     </a>",
"    </li>",
"    <li>",
"     Multistate Outbreak of Human Salmonella Infections Linked to Live Poultry, Initial announcement, May 30, 2012. file://www.cdc.gov/salmonella/live-poultry-05-12/index.html (Accessed on June 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/74\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: multistate outbreak of salmonella infantis, newport, and lille infections linked to live poultry from a single mail-order hatchery in ohio - march-september, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/75\">",
"      Finley R, Reid-Smith R, Weese JS. Human health implications of Salmonella-contaminated natural pet treats and raw pet food. Clin Infect Dis 2006; 42:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/76\">",
"      Centers for Disease Control and Prevention (CDC). Human salmonellosis associated with animal-derived pet treats--United States and Canada, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/77\">",
"      Steinmuller N, Demma L, Bender JB, et al. Outbreaks of enteric disease associated with animal contact: not just a foodborne problem anymore. Clin Infect Dis 2006; 43:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/78\">",
"      Olsen SJ, DeBess EE, McGivern TE, et al. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection. N Engl J Med 2001; 344:1572.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Human isolates final report, 2003 NARMS annual report. www.cdc.gov/narms/ (Accessed on May 06, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/80\">",
"      Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 1997; 24 Suppl 1:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/81\">",
"      Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/82\">",
"      Brown JC, Shanahan PM, Jesudason MV, et al. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996; 37:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/83\">",
"      Rowe B, Ward LR, Threlfall EJ. Ciprofloxacin-resistant Salmonella typhi in the UK. Lancet 1995; 346:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/84\">",
"      Chau TT, Campbell JI, Galindo CM, et al. Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2007; 51:4315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/85\">",
"      Kumar Y, Sharma A, Mani KR. High level of resistance to nalidixic acid in Salmonella enterica serovar Typhi in Central India. J Infect Dev Ctries 2009; 3:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/86\">",
"      Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008; 21:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/87\">",
"      Su LH, Chiu CH, Chu C, Ou JT. Antimicrobial resistance in nontyphoid Salmonella serotypes: a global challenge. Clin Infect Dis 2004; 39:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/88\">",
"      Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 2012; 55:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/89\">",
"      Glynn MK, Bopp C, Dewitt W, et al. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N Engl J Med 1998; 338:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/90\">",
"      Wall PG, Morgan D, Lamden K, et al. A case control study of infection with an epidemic strain of multiresistant Salmonella typhimurium DT104 in England and Wales. Commun Dis Rep CDR Rev 1994; 4:R130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/91\">",
"      Meakins S, Fisher IS, Berghold C, et al. Antimicrobial drug resistance in human nontyphoidal Salmonella isolates in Europe 2000-2004: a report from the Enter-net International Surveillance Network. Microb Drug Resist 2008; 14:31.",
"     </a>",
"    </li>",
"    <li>",
"     European Centre for Disease Prevention and Control. www.ecdc.europa.eu/en/Pages/home.aspx (Accessed on May 06, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/93\">",
"      Folster JP, Pecic G, Bolcen S, et al. Characterization of extended-spectrum cephalosporin-resistant Salmonella enterica serovar Heidelberg isolated from humans in the United States. Foodborne Pathog Dis 2010; 7:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/94\">",
"      Kruger T, Szabo D, Keddy KH, et al. Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother 2004; 48:4263.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. file://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/CephalosporinandAztreonamBreakpointRevisionFactSheet/CephalosporinAztreonamBreakpointFactSheet.pdf (Accessed on May 06, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/96\">",
"      M&oslash;lbak K, Baggesen DL, Aarestrup FM, et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N Engl J Med 1999; 341:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/97\">",
"      Herikstad H, Hayes P, Mokhtar M, et al. Emerging quinolone-resistant Salmonella in the United States. Emerg Infect Dis 1997; 3:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/98\">",
"      Threlfall EJ, Ward LR, Rowe B. Increasing incidence of resistance to trimethoprim and ciprofloxacin in epidemic Salmonella typhimurium DT104 in England and Wales. Euro Surveill 1997; 2:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14649/abstract/99\">",
"      Dutil L, Irwin R, Finley R, et al. Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg Infect Dis 2010; 16:48.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2683 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14649=[""].join("\n");
var outline_f14_19_14649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19743159\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACTERIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Salmonella typhi and Salmonella paratyphi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nontyphoidal Salmonellae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Foodborne infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18576815\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other methods of transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIMICROBIAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Salmonella typhi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nontyphoidal Salmonella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19743159\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2683|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/22/40301\" title=\"figure 1\">",
"      Incidence typhoid fever US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2683|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/6/4204\" title=\"table 1\">",
"      Salmonella serogroups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/10/40107\" title=\"table 2\">",
"      Foods causing Salmonellosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=related_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19033?source=related_link\">",
"      Pathogenesis of Salmonella gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=related_link\">",
"      Pathogenesis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=related_link\">",
"      Treatment and prevention of typhoid fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_19_14650="Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents";
var content_f14_19_14650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/19/14650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/19/14650/contributors\">",
"     Kevin R Krull, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/19/14650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/19/14650/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/19/14650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/19/14650/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/19/14650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in early childhood with symptoms of hyperactivity, impulsivity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inattention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/1\">",
"     1",
"    </a>",
"    ]. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning.",
"   </p>",
"   <p>",
"    Several types of medications are available to treat ADHD in children and adolescents: stimulants,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , alpha-2-adrenergic agonists, and antidepressants (",
"    <a class=\"graphic graphic_table graphicRef80151 \" href=\"UTD.htm?24/32/25101\">",
"     table 1",
"    </a>",
"    ). This topic will provide an overview of the pharmacology of medications used to treat ADHD in children and adolescents. Choosing a particular medication for an individual patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898686#H2007898686\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Choice of agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other topics related to ADHD are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link\">",
"       \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=see_link\">",
"       \"Adult attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STIMULANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulant drugs include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and amphetamines (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    and mixed",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/53/11096?source=see_link\">",
"     dextroamphetamine-amphetamine",
"    </a>",
"    salts). Stimulant drugs, with or without behavioral interventions, generally are the first-line treatment for school-aged children (&ge;6 years) and adolescents with uncomplicated ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Stimulants are controlled substances and require a schedule II prescription. Stimulants are available in short-, intermediate-, and long-acting formulations (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The exact mechanism of action of stimulants in ADHD is unknown. However, stimulants affect the dopaminergic and noradrenergic systems, causing the release of catecholamines from storage sites at the central nervous system (CNS) synapses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1220860245\">",
"    <span class=\"h2\">",
"     Methylphenidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    (eg, Ritalin, Methylin) is available as a tablet, chewable tablet, or liquid (",
"    <a class=\"graphic graphic_table graphicRef81815 \" href=\"UTD.htm?38/59/39869\">",
"     table 2A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. The time to initial effect ranges from 20 to 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2\">",
"     2",
"    </a>",
"    ]. The duration of action is three to five hours and the half-life is two to three hours.",
"   </p>",
"   <p>",
"    Long-acting",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    is available in tablets, capsules, oral suspension, and a patch [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/6\">",
"     6",
"    </a>",
"    ]. The onset and duration of action vary depending upon the formulation (",
"    <a class=\"graphic graphic_table graphicRef77580 \" href=\"UTD.htm?33/21/34142\">",
"     table 2B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single pulse wax matrix sustained release tablets (eg, Metadate-ER, Methylin-ER, Ritalin-SR) have onset of action within 20 to 60 minutes and last up to 8 hours.",
"     </li>",
"     <li>",
"      Sustained release capsules (eg, Focalin-XR, Metadate CD, Ritalin-LA) contain a mixture (usually one-to-one) of immediate release and enteric-coated delayed release beads (or pearls), and approximate a twice per day dosing schedule. They typically have onset of action within 20 to 60 minutes and may last up to 9 hours (up to 12 hours for extended release",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/9/17559?source=see_link\">",
"       dexmethylphenidate",
"      </a>",
"      [Focalin-XR]). Sustained release stimulant capsules can be opened and sprinkled on soft foods.",
"     </li>",
"     <li>",
"      Osmotic release",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      tablets (Concerta) are coated with immediate-release methylphenidate (for initial dosing) and use an osmotic pump to gradually release methylphenidate to approximate a three-times-per-day dosing schedule. Osmotic release methylphenidate usually has onset of action within 20 to 60 minutes and lasts up to 12 hours. Osmotic release methylphenidate tablets must be swallowed whole.",
"     </li>",
"     <li>",
"      The oral suspension (Quillivant XR) is a racemic mixture of the d- and l-isomers of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      ; the d-isomer is more active. It has onset of action within one hour and lasts as long as 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      patch (Daytrana) delivers methylphenidate transdermally. The methylphenidate patch has onset of action of 60 minutes. The duration of action may be as long as 12 hours, but can be controlled by early removal of the patch (the effects last approximately two to three hours after the patch is removed). The methylphenidate patch should not be cut [",
"      <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/7\">",
"       7",
"      </a>",
"      ]; if a lower dose is needed a smaller patch should be prescribed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose-response rate of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    is highly variable, and careful dose titration is necessary within the limitations of available formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Guidelines for the initial dose and dose titration for methylphenidate preparations are provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 2A-B",
"    </a>",
"    ). We do not suggest weight-based dosing, but as a general guide, significant reduction in core symptoms (ie, hyperactivity, impulsivity, and inattention) typically occurs at doses between 0.3 and 0.6",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/9/17559?source=see_link\">",
"     Dexmethylphenidate",
"    </a>",
"    (the d-enantiomer of methylphenidate) is generally efficacious at doses approximately one-half of those needed for methylphenidate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898721#H2007898721\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Amphetamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amphetamines can be prescribed as a single salt (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    ) or as mixed",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/53/11096?source=see_link\">",
"     dextroamphetamine-amphetamine",
"    </a>",
"    salts.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/14/37094?source=see_link\">",
"     Lisdexamfetamine",
"    </a>",
"    is a prodrug of dextroamphetamine that is pharmacologically activated after oral ingestion and was designed to discourage drug misuse [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amphetamine medications for ADHD are available in immediate- and sustained-release preparations (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 2A-B",
"    </a>",
"    ). The immediate-release preparation of mixed amphetamine salts (Adderall) has an onset of action of 20 to 60 minutes and a reported duration of up to six hours (",
"    <a class=\"graphic graphic_table graphicRef81815 \" href=\"UTD.htm?38/59/39869\">",
"     table 2A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longer-acting preparations (6 to 10 hours) of amphetamine and mixed amphetamine salts are available as capsules. The onset and duration of action vary depending upon the formulation (",
"    <a class=\"graphic graphic_table graphicRef77580 \" href=\"UTD.htm?33/21/34142\">",
"     table 2B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained release capsules (eg, Adderall XR, Dexedrine spansule) contain a mixture (usually one-to-one) of immediate release and enteric-coated delayed release beads (or pearls), and approximate a twice per day dosing schedule. They typically have onset of action within 20 to 60 minutes and last up to 10 hours. Sustained release amphetamine capsules can be opened and sprinkled on soft foods.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/14/37094?source=see_link\">",
"       Lisdexamfetamine",
"      </a>",
"      (Vyvanse) has onset of action within 60 minutes and lasts up to 10 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines for the initial dose and dose titration for amphetamine medications are provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Stimulant adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulants have been used to treat ADHD since the 1930s [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/12\">",
"     12",
"    </a>",
"    ] and generally are considered to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/13\">",
"     13",
"    </a>",
"    ]. Rare, serious adverse events have been reported in children being treated with stimulants, but a causal association has not been established. The potential risks of stimulants should be discussed with patients and families when choosing a management strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898679#H2007898679\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Pretreatment education'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although ADHD is common among children with epilepsy,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    does not appear to increase the frequency or severity of seizures in children who are receiving appropriate anticonvulsant medications and seizure free [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169251\">",
"    <span class=\"h3\">",
"     General adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the side effects of stimulants are mild, of short duration, and reversible with adjustments to the dose or dosing interval [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2166605#H2166605\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Managing stimulant adverse effects'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The frequency of side effects is similar with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and amphetamines. However, treatment with mixed",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/53/11096?source=see_link\">",
"     dextroamphetamine-amphetamine",
"    </a>",
"    salts may be associated with greater decrease in weight over time than treatment with methylphenidate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/18\">",
"     18",
"    </a>",
"    ]. Side effects may occur more frequently in preschool children than in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Relatively common side effects include anorexia, poor growth or weight loss, sleep disturbance, jitteriness, emotional lability (eg, social withdrawal), and the development of tics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Deceleration of linear growth may occur, but appears to attenuate over time; cessation of treatment may result in normalization of growth, and adult height does not appear to be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Growth should be regularly monitored during treatment with stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/5\">",
"     5",
"    </a>",
"    ]. Less common side effects include increased heart rate and blood pressure, headache, dizziness, and gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients treated with the methylphenidate patch may develop contact sensitization if the patch is worn in the same location every day [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/7,26\">",
"     7,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169258\">",
"    <span class=\"h3\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse cardiovascular effects of stimulants and the cardiac evaluation for children receiving pharmacotherapy for ADHD are discussed separately. Blood pressure and heart rate should be monitored before and during treatment with stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link\">",
"     \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169265\">",
"    <span class=\"h3\">",
"     Psychiatric effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents treated with stimulant medications rarely may develop psychotic symptoms (eg, hallucinations, delusional thinking, or mania) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In pooled analysis of data from 49 randomized clinical trials of drugs used to treat ADHD, the incidence of psychotic symptoms was 1.48 per 100",
"    <strong>",
"    </strong>",
"    person years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169280\">",
"    <span class=\"h3\">",
"     Tics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased tic frequency or development of tics may occur with stimulant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. In children who have chronic tics or Tourette syndrome (approximately 50 to 60 percent of whom have comorbid ADHD), low to moderate doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    often improve attention and behavior without worsening tics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. On the other hand, withdrawal of chronic methylphenidate in children with ADHD and Tourette syndrome can result in a decrease in frequency and severity of tics, with an increase when methylphenidate is reinitiated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/34\">",
"     34",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Two meta-analyses of studies evaluating treatment of ADHD in children with comorbid tic disorders found that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    prescribed at higher than the usual recommended doses was associated with exacerbation of tics, but methylphenidate was not [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Although predicting the effect of medication on tics is not possible, most children with tics and ADHD benefit from moderate doses of stimulants without worsening of tics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link&amp;anchor=H15#H15\">",
"     \"Tourette syndrome\", section on 'Attention deficit disorder and tics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169287\">",
"    <span class=\"h3\">",
"     Diversion and misuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulant diversion consists of the transfer of medication from the patient for whom it was prescribed to another individual [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/35\">",
"     35",
"    </a>",
"    ]. Stimulant misuse consists of taking higher doses of medication than prescribed to achieve euphoria or combining stimulant medications with illicit drugs or alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/35\">",
"     35",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    A systematic review of studies related to diversion and misuse of ADHD medications indicated that 5 to 9 percent of grade- and high-school-age students and 5 to 35 percent of college-age individuals reported nonprescribed stimulant use in the year before the study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/36\">",
"     36",
"    </a>",
"    ]. The proportion of students with stimulant prescriptions who were ever asked to give, sell, or trade their medications ranged from 16 to 29 percent. Diversion and misuse were more common among whites, members of fraternities and sororities, students with lower grade point averages, and students who report ADHD symptoms. Diversion and misuse also was more common with immediate- than extended-release preparations. The most commonly reported reasons for stimulant diversion and misuse included studying, staying awake, improved alertness, experimenting, and \"getting high\".",
"    <br/>",
"    <br/>",
"    In a survey that compared diversion and misuse of psychotropic medications (eg, stimulants, selective serotonin reuptake inhibitors, tricyclic antidepressants, alpha-adrenergic agonists, etc) among 55 adolescents and young adults with ADHD and 42 adolescents and young adults with other conditions, stimulant diversion and misuse were more frequent among subjects with ADHD than with other conditions (11 versus 0 percent for diversion and 22 versus 5 percent for misuse) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/35\">",
"     35",
"    </a>",
"    ]. All of the ADHD subjects who diverted or misused their medication had either comorbid conduct disorder or substance use disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2159402\">",
"    <span class=\"h2\">",
"     Contraindications to stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to stimulant medications may include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic cardiovascular disease",
"     </li>",
"     <li>",
"      Moderate to severe hypertension",
"     </li>",
"     <li>",
"      Hyperthyroidism",
"     </li>",
"     <li>",
"      Known hypersensitivity or idiosyncrasy to sympathomimetic amines",
"     </li>",
"     <li>",
"      Motor tics or Tourette syndrome",
"     </li>",
"     <li>",
"      Glaucoma",
"     </li>",
"     <li>",
"      Agitated states",
"     </li>",
"     <li>",
"      Anxiety",
"     </li>",
"     <li>",
"      History of drug abuse",
"     </li>",
"     <li>",
"      Concurrent use or use within 14 days of the administration of monoamine oxidase inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ATOMOXETINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    (Strattera) is a selective norepinephrine reuptake inhibitor that can be used to treat ADHD in children, adolescents, and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,3,20\">",
"     2,3,20",
"    </a>",
"    ]. It is not a controlled substance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/37\">",
"     37",
"    </a>",
"    ]. Atomoxetine is an alternative to stimulants for children (&ge;6 years) and adolescents who have a substance abuse problem, family member with a substance abuse problem, tics, or severe side effects with stimulants.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    is an oral capsule and can be taken once or twice per day; the capsule should be swallowed intact [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. When administered once daily, efficacy is better with morning than evening dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/38\">",
"     38",
"    </a>",
"    ]. However, evening dosing is associated with fewer overall adverse effects than morning dosing and may be better tolerated when initiating therapy (though no specific type of adverse event is more common with morning dosing).",
"   </p>",
"   <p>",
"    The duration of action of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    is at least 10 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2\">",
"     2",
"    </a>",
"    ]. Atomoxetine requires one to two weeks for initial response, and up to four weeks for maximum response; it must be given every day without &ldquo;drug holidays&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,39\">",
"     2,39",
"    </a>",
"    ]. Atomoxetine may be discontinued abruptly if a decision is made to discontinue it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898763#H2007898763\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Termination of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    depends upon the child&rsquo;s weight:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children and adolescents weighing &le;70 kg should be started at a dose of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for a minimum of three days and then titrated up to a daily dose of approximately 1.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in either one or two daily doses; the maximum daily dose should not exceed 1.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 100 mg, whichever is less.",
"     </li>",
"     <li>",
"      Patients who weigh more than 70 kg should be started at a dose of 40 mg for a minimum of three days, followed by an increase to approximately 80 mg; after two to four weeks, the dose may be increased to a maximum of 100 mg if additional benefit is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    is metabolized through the cytochrome P450 (CYP2D26) enzyme pathway. Dose adjustments may be necessary for patients receiving drugs that are strong inhibitors of CYP2D26 (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/5,40,41\">",
"     5,40,41",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     \"Atomoxetine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Atomoxetine adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169301\">",
"    <span class=\"h3\">",
"     General adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    include weight loss, abdominal pain, decreased appetite, vomiting, nausea, dyspepsia, headache, dizziness, somnolence, irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. The risk of adverse effects may be affected by genetic variations in the cytochrome P450 (CYP2D26) enzyme pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     \"Atomoxetine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169387\">",
"    <span class=\"h3\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    has stimulatory effect on the sympathetic nervous system and rare, but serious cardiovascular events, including sudden death, may occur during treatment with atomoxetine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/37,42\">",
"     37,42",
"    </a>",
"    ]. Children should be evaluated for cardiac disease before initiation of pharmacotherapy for ADHD. This evaluation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\", section on 'Cardiac evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2159697\">",
"    <span class=\"h3\">",
"     Suicidal thinking",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small number of patients,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    has been associated with an increased risk of suicidal thinking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/43\">",
"     43",
"    </a>",
"    ]. Combined analysis of 12 short-term (6 to 18 weeks) placebo-controlled trials of atomoxetine in 2208 patients (1357 of whom received atomoxetine) showed an increased risk of suicidal thinking among patients in the atomoxetine group (0.4 percent versus none of the controls; one patient in the atomoxetine group and none of the control patients attempted suicide) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/43\">",
"     43",
"    </a>",
"    ]. Atomoxetine has a boxed warning and additional warning statements regarding the increased risk of suicidal thinking in children and adolescents treated with atomoxetine.",
"   </p>",
"   <p>",
"    Children and adolescents taking",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    should be closely observed for clinical worsening, agitation, irritability, suicidal thinking or behaviors, and unusual changes in behavior, particularly during the first four to five months of therapy and when the dose is increased or decreased. The observation should include daily observation by families and caregivers and frequent contact with the prescribing physician. Additional information for patients and health care professionals is available from the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107912.htm\">",
"     United States Food and Drug Administration",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169469\">",
"    <span class=\"h3\">",
"     Psychiatric effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to suicidal thinking, other rare psychiatric adverse effects may occur during treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    . The psychiatric effects are similar to those described for stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H44169265\">",
"     'Psychiatric effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169309\">",
"    <span class=\"h3\">",
"     Tics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    use has been associated with the onset of motor tics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, in a randomized controlled trial in 148 children and adolescents with ADHD and comorbid tic disorders, treatment with atomoxetine did not exacerbate tic symptoms compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/46\">",
"     46",
"    </a>",
"    ]. Two meta-analyses of studies evaluating treatment of ADHD in children with comorbid tic disorders found that atomoxetine improved ADHD behaviors without exacerbating tics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44169294\">",
"    <span class=\"h3\">",
"     Liver injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiosyncratic severe liver injury has been reported in children and adults treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Among six patients reported to the FDA, the duration of treatment before liver injury varied from 3 weeks to 730 days (median 63 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/50\">",
"     50",
"    </a>",
"    ]. In one patient the evaluation was suggestive of type 1 autoimmune hepatitis, but the others had no alternative explanation for liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/47\">",
"     47",
"    </a>",
"    ]. None of the patients required liver transplantation, and most recovered after discontinuation of atomoxetine; there was one death, but it was not clear if atomoxetine caused or contributed to the death [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients taking",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    should contact their health care provider if they develop signs or symptoms of severe liver disease (eg, fatigue, anorexia, nausea, vomiting, pruritus, dark urine, jaundice, right upper quadrant tenderness, unexplained \"flu-like\" symptoms); liver enzymes should be measured [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/50\">",
"     50",
"    </a>",
"    ]. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury and cases of severe liver injury reported to the",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/default.htm\">",
"     US FDA MedWatch program",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2159581\">",
"    <span class=\"h2\">",
"     Contraindications to atomoxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    include (see",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     \"Atomoxetine: Pediatric drug information\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypersensitivity to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"       atomoxetine",
"      </a>",
"      or any component",
"     </li>",
"     <li>",
"      Concurrent use or use within 14 days of the administration of monoamine oxidase inhibitors",
"     </li>",
"     <li>",
"      Glaucoma",
"     </li>",
"     <li>",
"      Current or past history of pheochromocytoma",
"     </li>",
"     <li>",
"      Severe cardiovascular disorders in which increases in diastolic blood pressure &gt;15 mmHg, systolic blood pressure &gt;20 mmHg, or heart rate &gt;20 beats per minute would be expected to cause clinical deterioration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1130293854\">",
"    <span class=\"h1\">",
"     ALPHA-2-ADRENERGIC AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-2-adrenergic agonists (eg, extended release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    ) usually are reserved for children and adolescents who respond poorly to a trial of stimulants or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , have unacceptable side effects with stimulants or atomoxetine, or have significant comorbid conditions. Alpha-2-adrenergic agonists may take up to two weeks for initial response (compared with 20 minutes to a few hours for stimulants) and there are fewer data regarding their efficacy than for stimulants and atomoxetine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2,51\">",
"     2,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1130293861\">",
"    <span class=\"h2\">",
"     Extended release clonidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended-release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    (KAPVAY) can be used for the treatment of ADHD or as an adjunct to stimulant therapy for the treatment of ADHD in children and adolescents aged 6 to 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/52\">",
"     52",
"    </a>",
"    ]. Clonidine is not a controlled substance and has no known potential for abuse.",
"   </p>",
"   <p>",
"    Extended release and immediate release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    are not interchangeable on a mg-per-mg basis because they have different pharmacokinetic profiles. (See",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     \"Clonidine: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial dose of extended release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    is 0.1 mg at bedtime; the dose should be titrated to response in increments of 0.1 mg at weekly intervals (maximum 0.4",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Extended-release clonidine should be administered twice per day, divided equally or with the higher dose administered at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/52\">",
"     52",
"    </a>",
"    ]. The duration of action is at least 10 to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2\">",
"     2",
"    </a>",
"    ]. Discontinuation of clonidine requires tapering to prevent a rebound increase in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the few controlled studies that have been reported,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    was effective in reducing symptoms in patients with ADHD, but not as effective as stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The combination of extended-release clonidine and stimulant medication is also effective in reducing symptoms in children with a partial response to stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/55\">",
"     55",
"    </a>",
"    ]. Clonidine may be useful in overaroused, easily frustrated, highly active, or aggressive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/3\">",
"     3",
"    </a>",
"    ]. Although there are few randomized controlled trials with multiple drugs, the addition of clonidine to stimulant therapy may help offset some of the common stimulant side effects.",
"   </p>",
"   <p>",
"    In two meta-analyses, alpha-2-adrenergic agonists were associated with improvements in ADHD symptoms and comorbid tics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     Clonidine",
"    </a>",
"    has been used without increased morbidity in children with ADHD and comorbid tics or Tourette syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    include sedation, depression, bradycardia, headache, and possible hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Oral clonidine may cause generalized rash, urticaria, or angioedema in patients with a history of hypersensitivity reactions to transdermal clonidine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1130293868\">",
"    <span class=\"h2\">",
"     Extended release guanfacine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended-release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    (Intuniv) can be used for once-daily treatment of ADHD or as an adjunct to stimulant therapy in children and adolescents aged 6 to 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Guanfacine has a longer half-life and fewer side effects than does",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Extended release and immediate release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    are not interchangeable on an mg-per-mg basis because of differences in bioavailability. (See",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     \"Guanfacine: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extended-release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    is administered once per day [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2\">",
"     2",
"    </a>",
"    ]. The initial dose is 1 mg per day; the dose should be titrated to response in increments of 1 mg at weekly intervals (maximum 4",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    The duration of action is at least 10 to 12 hours. Extended release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    requires one to two weeks for initial response. Discontinuation of guanfacine requires tapering to prevent a rebound increase in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial in 345 patients (6 to 17 years), extended-release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    was efficacious in improving ADHD symptoms compared with placebo (reduction in ADHD-RS-IV score of 16.7 versus 9.7 points); adverse effects included headache, fatigue, abdominal pain, and sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/61\">",
"     61",
"    </a>",
"    ]. Similar results were found in a second phase III trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two meta-analyses, alpha-2-adrenergic agonists were associated with improvements in ADHD symptoms and comorbid tics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     Guanfacine",
"    </a>",
"    has been used in open or small trials to treat children with ADHD and Tourette syndrome whose tics worsened with stimulants or in whom",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    was poorly tolerated (either because of its sedative side effects or short duration) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/32,33,63,64\">",
"     32,33,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants that have been used in the treatment of ADHD include tricyclic antidepressants (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/5/31831?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/16/36103?source=see_link\">",
"     desipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/26/38310?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ), and dopamine reuptake inhibitors (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=see_link\">",
"     bupropion",
"    </a>",
"    ). These medications usually are reserved for children and adolescents who respond poorly to a trial of stimulants or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , have unacceptable side effects, or have significant comorbid conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1130293643\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants inhibit the reuptake of norepinephrine and serotonin. With the availability additional nonstimulant medications, tricyclic antidepressants usually are reserved for children and adolescents who respond poorly to a trial of stimulants,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    or beta-2-adrenergic agonists, have unacceptable side effects with these medications, or have significant comorbid conditions.",
"   </p>",
"   <p>",
"    In a systematic review of six studies evaluating the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/16/36103?source=see_link\">",
"     desipramine",
"    </a>",
"    and three studies evaluating the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/5/31831?source=see_link\">",
"     imipramine",
"    </a>",
"    for the treatment of ADHD in children, all of the studies indicated a positive response on ADHD symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/65\">",
"     65",
"    </a>",
"    ]. Review of four trials comparing tricyclic antidepressants and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    indicated either no difference in response or slightly better results with stimulant use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/65\">",
"     65",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Tricyclic antidepressants have been associated with adverse cardiovascular events. Additional side effects that may limit the usefulness of tricyclic antidepressants include anticholinergic effects (eg, dry mouth, constipation) and lowering of the seizure threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Before tricyclic antidepressants are used to treat ADHD in children, a review of the patient's history (for heart disease and symptoms including palpitations, dizziness, syncope, or near syncope) and family history (for sudden unexpected death at less than 40 years, long QT syndrome or other arrhythmias, and hypertrophic cardiomyopathy) should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, an electrocardiogram should be obtained at baseline and when the dose has been optimized because tricyclic antidepressants can cause arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In children with resting heart rate &ge;130",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    PR interval &gt;200 millisec, QRS &gt;120 millisec, QTc &gt;460 millisec, or symptoms such as palpitations, syncope, or near syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], treatment with drugs other than tricyclic antidepressants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pediatric cardiology consultation may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1130293658\">",
"    <span class=\"h2\">",
"     Bupropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=see_link\">",
"     Bupropion",
"    </a>",
"    , an antidepressant that blocks the reuptake of norepinephrine and dopamine, has more stimulant properties than the tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/68\">",
"     68",
"    </a>",
"    ]. It is of modest efficacy in decreasing hyperactivity and aggressive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/68\">",
"     68",
"    </a>",
"    ]. Adverse effects include irritability, anorexia, insomnia, motor tics, and a decreased seizure threshold (at doses greater than 450",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs being investigated for the treatment of ADHD include anticholinesterase inhibitors (tacrine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ) and nicotinic analogues (ABT-418) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In controlled trials,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=see_link\">",
"     modafinil",
"    </a>",
"    (Sparlon, marketed as Provigil), another stimulant, appeared to improve the core symptoms of ADHD compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. However, it was associated with serious dermatologic and psychiatric reactions (eg, Stevens Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, anxiety, mania, hallucinations, suicidal ideation) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. It is not approved for use in children for any indication [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/73\">",
"     73",
"    </a>",
"    ]; the United States Food and Drug Administration&rsquo;s (FDA) Pediatrics Advisory Committee has unanimously recommended that the label include language that specifically warns against its use in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/19/14650/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/42/3746?source=see_link\">",
"       \"Patient information: Medicines for attention deficit hyperactivity disorder (ADHD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=see_link\">",
"       \"Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/53/35668?source=see_link\">",
"       \"Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several types of medications are available to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents: stimulants,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"       atomoxetine",
"      </a>",
"      , alpha-2-adrenergic agonists, and antidepressants. Choosing a particular medication for an individual patient is discussed separately (",
"      <a class=\"graphic graphic_table graphicRef80151 \" href=\"UTD.htm?24/32/25101\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898686#H2007898686\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Choice of agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stimulant drugs include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      and amphetamines. Stimulants are controlled substances and require a schedule II prescription. Stimulants are available in short-, intermediate-, and long-acting formulations (",
"      <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Stimulants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stimulants generally are considered safe, with mild, reversible side effects. However, there have been rare reports of serious adverse events, including sudden unexpected death. The potential risks of stimulants should be discussed with patients and families when choosing a management strategy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Stimulant adverse effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898679#H2007898679\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Pretreatment education'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"       Atomoxetine",
"      </a>",
"      is a selective norepinephrine reuptake inhibitor. It is not a controlled substance. Atomoxetine generally is considered safe, but there have been rare reports of serious adverse effects, including liver injury and an increased risk of suicidal thinking (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Atomoxetine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alpha-2-adrenergic agonists (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"       guanfacine",
"      </a>",
"      ) and antidepressants (eg, tricyclic antidepressants,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/11/39096?source=see_link\">",
"       bupropion",
"      </a>",
"      ) usually are reserved for children or adolescents who respond poorly to a trial of stimulants or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"       atomoxetine",
"      </a>",
"      , have unacceptable side effects with stimulants or atomoxetine, or have significant comorbid conditions. (See",
"      <a class=\"local\" href=\"#H1130293854\">",
"       'Alpha-2-adrenergic agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th, American Psychiatric Association, Washington, DC 2000. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/2\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/3\">",
"      Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/4\">",
"      Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/5\">",
"      Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48:240.",
"     </a>",
"    </li>",
"    <li>",
"     Quillivant XR prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2012/202100lbl.pdf (Accessed on November 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/7\">",
"      Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011; 58:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/8\">",
"      Hill P, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001; 84:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/9\">",
"      Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/10\">",
"      Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997; 131:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/11\">",
"      Blick SK, Keating GM. Lisdexamfetamine. Paediatr Drugs 2007; 9:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/12\">",
"      Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937; 94:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/13\">",
"      Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/14\">",
"      Gross-Tsur V, Manor O, van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997; 130:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/15\">",
"      Wroblewski BA, Leary JM, Phelan AM, et al. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992; 53:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/16\">",
"      Gucuyener K, Erdemoglu AK, Senol S, et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/17\">",
"      Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004; 61:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/18\">",
"      Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/19\">",
"      Firestone P, Musten LM, Pisterman S, et al. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/20\">",
"      Harpin VA. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 2008; 93:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/21\">",
"      Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/22\">",
"      Kramer JR, Loney J, Ponto LB, et al. Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 2000; 39:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/23\">",
"      Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007; 46:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/24\">",
"      Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/25\">",
"      Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 2010; 157:635.",
"     </a>",
"    </li>",
"    <li>",
"     Daytrana prescribing information. Available at file://pi.shirecontent.com/PI/PDFs/Daytrana_USA_ENG.pdf (Accessed on August 31, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/27\">",
"      Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006; 163:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/28\">",
"      Mosholder AD, Gelperin K, Hammad TA, et al. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009; 123:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/29\">",
"      Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995; 52:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/30\">",
"      Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/31\">",
"      Nass R, Bressman S. Attention deficit hyperactivity disorder and Tourette syndrome: what's the best treatment? Neurology 2002; 58:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/32\">",
"      Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/33\">",
"      Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011; :CD007990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/34\">",
"      Riddle MA, Lynch KA, Scahill L, et al. Effects of methylphenidate discontinuation and reinitiation in children with Tourette's syndrome and ADHD. J Child Adolesc Psychopharmacol 1995; 5:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/35\">",
"      Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/36\">",
"      Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:21.",
"     </a>",
"    </li>",
"    <li>",
"     Strattera (atomoxetine hydrochloride) capsules for oral use. Prescribing information. pi.lilly.com/us/strattera-pi.pdf (Accessed on July 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/38\">",
"      Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila) 2009; 48:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/39\">",
"      Schonwald A. Update: attention deficit/hyperactivity disorder in the primary care office. Curr Opin Pediatr 2005; 17:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/40\">",
"      Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/41\">",
"      Drugs for treatment of ADHD. Treat Guidel Med Lett 2006; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/42\">",
"      Rajesh AS, Bates G, Wright JG. Atomoxetine-induced electrocardiogram changes. Arch Dis Child 2006; 91:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/43\">",
"      Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008; 47:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/44\">",
"      Lee TS, Lee TD, Lombroso PJ, King RA. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 2004; 43:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/45\">",
"      Ledbetter M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol 2005; 15:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/46\">",
"      Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/47\">",
"      Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006; 148:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/48\">",
"      Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/49\">",
"      Stojanovski SD, Casavant MJ, Mousa HM, et al. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila) 2007; 45:51.",
"     </a>",
"    </li>",
"    <li>",
"     Atomoxetine (marketed as Strattera) serious liver injury. FDA Drug Safety Newsletter 2009. file://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm110235.htm (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/51\">",
"      Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366:237.",
"     </a>",
"    </li>",
"    <li>",
"     KAPVAY (clonidine hydrochloride) extended-release tablets prescribing information. Shionogi Pharma, Inc. Atlanta, GA 2010. www.kapvay.com/Kapvay_final_09.28.10.pdf (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/53\">",
"      Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/54\">",
"      Palumbo DR, Sallee FR, Pelham WE Jr, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/55\">",
"      Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011; 127:e1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/56\">",
"      Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23 Suppl 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/57\">",
"      Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/58\">",
"      Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42:886.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Approved Drug Products www.accessdata.fda.gov/Scripts/cder/DrugsatFDA (Accessed on May 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/60\">",
"      Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/61\">",
"      Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121:e73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/62\">",
"      Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/63\">",
"      Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/64\">",
"      Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/65\">",
"      Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999; :i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/66\">",
"      Gutgesell H, Atkins D, Barst R, et al. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1999; 38:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/67\">",
"      Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/68\">",
"      Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996; 35:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/69\">",
"      Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry 2000; 9 Suppl 1:I51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/70\">",
"      Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005; 116:e777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/71\">",
"      Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006; 67:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/19/14650/abstract/72\">",
"      Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008; 152:394.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. 2007 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152701.htm (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     Provigil label: Panel&rsquo;s &ldquo;not recommended&rdquo; language could be template. In:  \"The Pink Sheet\" FDC Reports, Chevy Chase, MD, December 10, 2007. p.12.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 621 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14650=[""].join("\n");
var outline_f14_19_14650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STIMULANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1220860245\">",
"      Methylphenidate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Amphetamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stimulant adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169251\">",
"      - General adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169258\">",
"      - Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169265\">",
"      - Psychiatric effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169280\">",
"      - Tics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169287\">",
"      - Diversion and misuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2159402\">",
"      Contraindications to stimulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ATOMOXETINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Atomoxetine adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169301\">",
"      - General adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169387\">",
"      - Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2159697\">",
"      - Suicidal thinking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169469\">",
"      - Psychiatric effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169309\">",
"      - Tics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44169294\">",
"      - Liver injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2159581\">",
"      Contraindications to atomoxetine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1130293854\">",
"      ALPHA-2-ADRENERGIC AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1130293861\">",
"      Extended release clonidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1130293868\">",
"      Extended release guanfacine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1130293643\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1130293658\">",
"      Bupropion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INVESTIGATIONAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/621|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/32/25101\" title=\"table 1\">",
"      ADHD drugs comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/59/39869\" title=\"table 2A\">",
"      Immediate release preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/21/34142\" title=\"table 2B\">",
"      Long-acting meds for ADHD in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=related_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=related_link\">",
"      Atomoxetine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=related_link\">",
"      Atomoxetine: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=related_link\">",
"      Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=related_link\">",
"      Clonidine: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=related_link\">",
"      Guanfacine: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/42/3746?source=related_link\">",
"      Patient information: Medicines for attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=related_link\">",
"      Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/53/35668?source=related_link\">",
"      Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_19_14651="Motion sickness pharmacotherapy";
var content_f14_19_14651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common pharmacologic therapies for motion sickness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antidopaminergics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Promethazine (Anergan, Phenergan)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metoclopramide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Anticholinergic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Scopolamine (Transderm-Scop)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Antihistamines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meclizine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diphenhydramine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dimenhydrinate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyclizine (Marezine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Buclizine (Bucladin-S Softabs)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trimethobenzamide",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Information from: Gahlinger PM. Motion sickness: how to help your patients avoid travel travail. Postgraduate Medicine 1999; 106:177. Copyright &copy;1999 McGraw Hill Companies.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14651=[""].join("\n");
var outline_f14_19_14651=null;
var title_f14_19_14652="Breast MRI mam occult breast CA";
var content_f14_19_14652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Utility of breast MRI for mammographically-occult breast cancer in patients presenting with metastatic axillary lymphadenopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        MRI-positive, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histologic diagnosis of breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morris, E; 1997",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        9 (75)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brenner, R; 1997",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4 (100)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tilanus-Linthorst, M; 1997",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4 (100)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schorn, C; 1999",
"       </td>",
"       <td>",
"        14&bull;",
"       </td>",
"       <td>",
"        9 (64)",
"       </td>",
"       <td>",
"        6/9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Henry-Tillman, R; 1999",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        8 (80)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Olson, J; 2000",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        28 (70)",
"       </td>",
"       <td>",
"        21/22*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obdeijn, I; 2000",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        8 (40)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fourquet, A; 2004",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        14 (93)",
"       </td>",
"       <td>",
"        9/11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Buchanan, C; 2005",
"       </td>",
"       <td rowspan=\"2\">",
"        69",
"       </td>",
"       <td rowspan=\"2\">",
"        42 (76)",
"       </td>",
"       <td>",
"        26/42 MRI+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4/12 MRI-",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Number of patients with confirmed MRI findings at the time of surgery.",
"     <br>",
"      &bull; Included six axillary nodal metastases, one supraclavicular nodal metastases, three bone metastases, three liver metastases, and one lung metastases with an unknown primary.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14652=[""].join("\n");
var outline_f14_19_14652=null;
var title_f14_19_14653="Microbiology of prosthetic valve endocarditis";
var content_f14_19_14653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Microbiology of prosthetic valve endocarditis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Number of cases (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Time of onset after valve surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        &lt;2 months",
"        <br/>",
"        n = 199",
"       </td>",
"       <td class=\"subtitle3\">",
"        2 to 12 months",
"        <br/>",
"        n = 47",
"       </td>",
"       <td class=\"subtitle3\">",
"        &gt;12 months",
"        <br/>",
"        n = 282",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptococci*",
"       </td>",
"       <td class=\"centered\">",
"        4 (2)",
"       </td>",
"       <td class=\"centered\">",
"        6 (13)",
"       </td>",
"       <td class=\"centered\">",
"        84 (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumococci",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &lt;1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterococci",
"       </td>",
"       <td class=\"centered\">",
"        16 (8)",
"       </td>",
"       <td class=\"centered\">",
"        5 (11)",
"       </td>",
"       <td class=\"centered\">",
"        31 (11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        56 (28)",
"       </td>",
"       <td class=\"centered\">",
"        6 (13)",
"       </td>",
"       <td class=\"centered\">",
"        62 (22)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulase negative staphylococci",
"       </td>",
"       <td class=\"centered\">",
"        60 (30)",
"       </td>",
"       <td class=\"centered\">",
"        17 (36)",
"       </td>",
"       <td class=\"centered\">",
"        34 (12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HACEK Group",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        11 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram negative bacilli",
"       </td>",
"       <td class=\"centered\">",
"        23 (12)",
"       </td>",
"       <td class=\"centered\">",
"        2 (4)",
"       </td>",
"       <td class=\"centered\">",
"        13 (5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungi (Candida species)",
"       </td>",
"       <td class=\"centered\">",
"        17 (8)",
"       </td>",
"       <td class=\"centered\">",
"        4 (8)",
"       </td>",
"       <td class=\"centered\">",
"        3 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymicrobial/miscellaneous",
"       </td>",
"       <td class=\"centered\">",
"        7 (3)",
"       </td>",
"       <td class=\"centered\">",
"        4 (8)",
"       </td>",
"       <td class=\"centered\">",
"        12 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diphtheroids",
"       </td>",
"       <td class=\"centered\">",
"        9 (4)",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        5 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Culture negative",
"       </td>",
"       <td class=\"centered\">",
"        7 (3)",
"       </td>",
"       <td class=\"centered\">",
"        3 (6)",
"       </td>",
"       <td class=\"centered\">",
"        27 (10)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes Viridans streptococci,",
"     <em>",
"      S. gallolyticus",
"     </em>",
"     (previously",
"     <em>",
"      S. bovis",
"     </em>",
"     biotype 1), other non-groupable and groupable streptococci.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Includes",
"     <em>",
"      Hemophilus",
"     </em>",
"     species,",
"     <em>",
"      Aggregatibacter aphrophilus",
"     </em>",
"     ,",
"     <em>",
"      Aggregatibacter actinomycetemcomitans",
"     </em>",
"     ,",
"     <em>",
"      Cardiobacterium hominis",
"     </em>",
"     ,",
"     <em>",
"      Eikenella",
"     </em>",
"     species,",
"     <em>",
"      Kingella kingae",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Rivas P, Alonso J, Moya J, et al. The impact of hospital-acquired infections on the microbial etiology and prognosis of late-onset prosthetic valve endocarditis. Chest 2005; 128:764.",
"      </li>",
"      <li>",
"       Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin North Amer 2002; 16:477.",
"      </li>",
"      <li>",
"       Hill EE, Herregods MC, Vanderschueren S, et al. Management of prosthetic valve infective endocarditis. Am J Cardiol 2008; 101:1174.",
"      </li>",
"      <li>",
"       Lee JH, Burner JD, Fealey ME, et al. Prosthetic valve endocarditis: Clinicopathological correlates in 122 surgical specimens from 116 patients (1985-2004). Cardiovasc Pathol 2011; 20:26.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14653=[""].join("\n");
var outline_f14_19_14653=null;
var title_f14_19_14654="Renin release";
var content_f14_19_14654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Regulation of renin release",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 417px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The renin-angiotensin-aldosterone system and the maintenance of sodium and volume balance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14654=[""].join("\n");
var outline_f14_19_14654=null;
var title_f14_19_14655="CXR bronchiect child";
var content_f14_19_14655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest x-ray of a pediatric patient with bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The airways are dilated and thickened, as indicated by parallel linear opacities (tram tracking) when seen longitudinally, and ring shadows on cross section (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Drs. Khoulood Fakhoury and Adaobi Kanu.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_19_14655=[""].join("\n");
var outline_f14_19_14655=null;
